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INVESTIGATING THE ROLES OF TAP63 AND TAP73 IN CUTANEOUS
SQUAMOUS CELL CARCINOMA AND LUNG ADENOCARCINOMA.
Andrew John Davis, B.S.
Advisory Professor: Elsa R. Flores, Ph.D.
TP63 and TP73 (which encode p63 and p73, respectively) are highly conserved
transcription factors with important roles in development and tissue homeostasis.
Similar to their homolog, p53, both p63 and p73 have been shown to mediate tumor
suppression in multiple tissue types. Interestingly, however, both genes are
expressed as multiple isoforms, which appear to have different and, in many cases,
antagonistic functions. Through the use of isoform-specific null alleles of p63 and
p73 our lab and others have shown that the full-length N-terminal isoforms of p63
and p73 (referred to as TAp63 and TAp73, respectively) exhibit distinct functions in
development, metabolism and tumor suppression. My thesis research focuses on
understanding the conserved functions of TAp63 and TAp73 in tumorigenesis. To do
so, I have utilized multiple model systems to investigate the contributions of TAp63
and TAp73 in the development and progression of cutaneous squamous cell
carcinoma (cuSCC) and lung adenocarcinoma (LUAC). I have found that TAp63-null
(TAp63-/-) mice exhibit increased susceptibility to UVR-induced cuSCC. To identify
TAp63-regulated transcriptional programs relevant to the pathophysiology cuSCC,
we performed RNA sequencing of cuSCC and normal tissues from wild-type (WT)
and TAp63-/- mice. My data revealed significant perturbations in global miRNA and
mRNA expression in TAp63-deficient tumors, which resembled similar transcriptional
changes in human cuSCC, including the downregulation of miR-30c-2* and miR-
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497. Proteomic profiling of cuSCC cell lines and subsequent validation experiments
led to the discovery of novel direct targets of miR-497 and miR-30c-2*. The most
relevant of these proteins exhibited pro-oncogenic functions, including roles in cell
cycle and mitotic progression. My data establishes TAp63 as an essential regulator
of miRNA expression during skin carcinogenesis and reveals a previously
undescribed network of miRNAs and mRNAs, which include viable, yet previously
unexplored targets for therapeutic intervention. Along with TAp63-mediated tumor
suppression in the skin, I have also developed a novel TAp73 conditional knockout
mouse, which includes a conditional fluorescent reporter (TAp73fltd) that allows us to
follow the deletion event at the cellular level. Using this model we have found that
the loss of TAp73 accelerates the initiation and progression of oncogenic Krasdriven LUAC. Our data suggests that TAp73 may be necessary for anti-tumor
immune responses. In addition, we have found that the loss of TAp73 promotes
migration and invasion in human LUAC cell lines. These studies suggest that TAp73
can suppress tumor development and progression through both cell-autonomous
and non-cell-autonomous mechanisms. Together, the studies described in this
dissertation provide insights into the genetic and epigenetic mechanisms that
contribute to cuSCC and LUAC development, which may, in turn, inform future
biomarker and drug discovery studies.
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CHAPTER 1: INTRODUCTION
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Chapter 1: INTRODUCTION
1.1. The p53/p63/p73 family of transcription factors
1.1.1. An overview
This dissertation is comprised of two related projects focused on understanding the
conserved functions of TAp63 and TAp73 in tumorigenesis. To do so, I have utilized
multiple model systems to investigate the contributions of each of these genes to the
development and progression of cutaneous squamous cell carcinoma (cuSCC) and
lung adenocarcinoma (LUAC). These model systems include genetically engineered
mouse models (GEMMs), human cancer cell lines, and orthotopic tumor models.
Using these model systems I have uncovered tumor suppressive functions for
TAp63 and TAp73 in cuSCC and LUAC, respectively. Molecular and biochemical
assays were employed to probe the specific mechanisms through which these
genes mediate tumor suppression, in both mice and humans. Through these studies
I have uncovered and described multiple conserved functions for TAp63 and TAp73
in the pathogenesis of human cancer. Ultimately, the insights we have made may
inform future biomarker studies and the design of targeted therapies for cuSCC and
LUAC.
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Figure 1: p53, p63 and p73 are homologous transcription factors that are
expressed as complex isoforms. The exonic structure of p63 (maroon) and p73
(tan), with approximate sequence homology to p53. Importantly, p63 and p73 are
expressed as multiple, complex isoforms, due to the presence of 2 alternative
promoters and alternative splicing at the 3’ end of both genes. This in turn results in
the expression of at least 2 sub-classes of p63 and p73 isoforms, which are typically
referred to as TAp63/∆Np63 and TAp73/∆Np73 respectively.
(This figure is reproduced from Su X, Chakravarti D, Flores ER. p63 steps into the
limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev
Cancer. 2013; 13(2):136-43 (1), with permission from Copyright Clearance Center)
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1.1.2. Isoform-specific functions of p63 and p73
In recent years, significant progress has been made in understanding the roles of
the TP63 and TP73 genes in tumor suppression and normal development. Both
have been shown to regulate a number of genes involved in apoptosis, cell cycle
regulation (2, 3), DNA repair (4, 5), metabolism (6-9), immunity (10, 11), cellular
adhesion (12, 13), stemness (14), and cellular differentiation (15-18).
Interestingly, early studies suggested that TP63 and TP73 could be tumor
promoting, as they were frequently amplified or overexpressed in certain tumor types
(19, 20). These seemingly contradictory observations were explained by the
expression of multiple TP63 and TP73 transcript isoforms, which have been shown
to exhibit distinct, as well as antagonistic functions (21, 22). Full-length isoforms
expressed from the 5’ promoter contain an N-terminal transactivation domain
(referred to as TAp63 and TAp73), and are thus structurally and functionally similar
to p53 (Figure 1) (1, 21, 23). In fact, studies have shown that the presence of this
domain allows TAp63 and TAp73 to similarly regulate many of the canonical p53
target genes (4, 6, 21, 24). In contrast, the isoforms that are expressed from the
downstream 3’ promoter lack the N-terminal transactivation domain (referred to as
ΔNp63 and ΔNp73), and are thus unable to transcriptionally activate canonical p53
target genes (3, 21, 25, 26). Interestingly, however, there is growing evidence that
ΔN isoforms can activate transcription (27, 28). In fact, our laboratory has
demonstrated that the α, β, and γ isoforms of ΔNp63 can transactivate DGCR8
expression, whereas TAp63 isoforms have no effect on DGCR8 expression (29).
Nevertheless, multiple studies have shown that ΔNp63 and ΔNp73 isoforms can
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antagonize the transcriptional activities of p53, TAp63, and TAp73 and can thus
function as oncogenes when overexpressed (6, 30, 31). For example, ΔNp63 has
been shown to bind and repress the transcription of well-characterized tumor
suppressors, including p21WAF1/Cip1 and 14-3-3σ (32). Accordingly, we have explored
the possibility of targeting and inhibiting ΔNp63 and ΔNp73 as therapeutic strategies
for the treatment of human cancers (6, 33, 34).
Taken together, research of p63 and p73 has revealed several important
functions for each gene in normal development and human diseases, including
cancer. While these observations have been complicated by the presence of
multiple isoforms of each gene, significant progress has been made in elucidating
the various roles each isoform plays in different cellular and physiological contexts.

1.2. p63 isoforms in epithelial development and tumor suppression
1.2.1. Epithelial development and homeostasis
The skin is the largest organ system in the body, and consists of the dermis,
basement membrane, and epidermis. Together, the skin provides protection from
external physical damage, infection from microbes, and prevents fluid loss and
dehydration. The epidermis contains a number of different appendages including
hair follicles (HFs), sweat glands (SWGs), sebaceous glands (SGs), and nails (35).
While hair follicles mediate thermal regulation, they also function as anchors for
arrector pili muscles, blood vessels, and sensory neurons (36).
During early development in mice the surface of the ectoderm is lined by a
single-layered epithelium, which is characterized by the expression of cytokeratin 18
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(K18) (37). Thickening and stratification of the epidermis begins on embryonic day
E9.5, and this event is accompanied by de novo expression of cytokeratin 5 (K5)
and 14 (K14). The spinous and granular layers form around E15.5, each of which is
characterized by the expression of the differentiation markers cytokeratin 1 (K1) and
loricrin (38). Epidermal development and stratification concludes on E19.5, just prior
to birth.
In adult mice, the epidermis and its appendages experience continuous
turnover to replenish damaged and dying cells, and to maintain the integrity of the
tissue structures. Multiple stem cell compartments reside within the IFE and the
various epidermal appendages, consisting of cells that can self renew and produce
more differentiated progenitors (39-42). The IFE is continuously replenished by the
proliferation of basal keratinocytes, which includes basal stem cells and transit
amplifying cells (TACs) (36). These cells express K5 and K14 and lay atop the
basement membrane. This structure contains a dense extracellular matrix (ECM)
and secretes important growth factors that supports the IFE. Basal stem cells and
TACs express multiple integrins, including α6β4 and α3β1, which bind to laminin-5 in
the basement membrane and contribute to cell polarity (43). Adherens junctions and
desmosomes also mediate cell polarity, through their abilities in establishing
intercellular connections between the various epithelial cells within the epidermis
(44).
Together, basal stem cells and TACs fuel the stratification of the epidermis.
This process is regulated by two primary mechanisms: (1) asymmetric cell division,
in which cells divide in a vertical plane, relative to the basement membrane (45), and
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(2) delamination, which is the process by which basal keratinocytes detach from the
basement membrane and migrate out towards the suprabasal layers (46). This
process results in a proliferative basal cell and a suprabasal daughter cell that is
committed to differentiation (45). As basal keratinocytes detach from the basement
membrane, they exit the cell cycle, and migrate from the inner basal layer to the
outer, apical layer of the epidermis. During this process, keratinocytes undergo
differentiation, which includes a tightly regulated program of biochemical and
morphological changes, including permanent cell cycle arrest, enucleation, and
cornification (47). These changes result in several distinct layers of keratinocytes in
various stages of differentiation. These layers are referred to as the basal layer,
spinous layer, granular layer and the stratum corneum, which lines the apical
surface (Figure 2). The outermost layer consists of dead, enucleated squamous cells
(referred to as squames). These cells lack most of its organelles and consist
primarily of insoluble bundles of keratin filaments. Adjacent squames are fused to
one another via lipid bilayers that are secreted during terminal differentiation. This
adhesion forms a tight barrier that prevents fluid loss and blocks microbes from
entering the host. Squames are continuously sloughed off from the apical surface
and are replenished by the underlying keratinocytes.
Most mammals, including mice and humans, develop and maintain a hair
coat, which consists of HFs found throughout the organisms skin. Proper HF
development and maintenance requires frequent regeneration of new hairs
throughout the life of the animal (48). In contrast to the IFE, which undergoes
continuous regeneration, hair follicles undergo cycles of regeneration interrupted by
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periods of quiescence. This process is driven by signaling between stem cells
located in a region known as the bulge, clusters of cells below the bulge known as
the hair germ, and dermal fibroblasts (36). Hair cycles are driven by two populations
of hair follicle stem cells (HFSCs): (1) a quiescent population found in the bulge (BuSCs) and (2) another proliferative population located within the hair germ below the
bulge region (49). Together, these stem cells are responsible for follicular
morphogenesis and homeostasis.
The hair cycle is characterized by distinct phases, including anagen (hair
follicle growth), catagen (follicle regression), and telogen (quiescence). During
anagen, the hair shaft grows from the root via proliferation and differentiation of hair
matrix cells within the bulb. At the beginning of anagen, the cells within the hair germ
begin to proliferate (49). These cells develop into a pool of transit amplifying matrix
cells, which proliferate prior to terminally differentiating into the inner root sheath
(IRS) and the hair shaft (HS). Bu-SCs primarily develop into the outer root sheath
(ORS), which is a group of cells with features of stem cells that surround the
differentiating core of each HF (50).
Following anagen, HFs begin to regress and enter catagen. During this
phase, cell proliferation within the hair bulb stops, differentiation ceases, and cells
undergo extensive apoptosis (48). Subsequently, during the catagen-to-telogen
transition, apoptosis ceases, a HS club is anchored, and the HF enters the quiescent
telogen phase. ORS cells give rise to a new hair germ and form a new bulge
adjacent to the previous one (50). The cells in the new bulge contain HFSCs, which
are required for the subsequent hair cycle. Interestingly, the HFSCs present in the
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original bulge are a reserve of HFSCs, which can be recruited during epidermal
wounding.
Throughout telogen, HFSCs in the bulge and hair germ communicate with a
dermal structure known as the dermal papilla (DP). This process involves several
inhibitory and growth promoting signaling pathways (49, 51). When the balance of
signaling cues favors activation, HFSCs within the hair germ divide and initiate
renewed hair morphogenesis (49).
The DP derives from mesenchymal precursors and they are essential for hair
follicle induction (52). The adult DP comprises a niche for a stem cell population
known as skin derived precursors (SKPs) (53, 54). These stem cells derive from
dermal precursors that express SOX2 and exhibit features of embryonic neural crest
stem cells (53). SKP cells are found in both the DP and the dermal sheath (DS).
These cells are necessary for normal HF morphogenesis, tissue maintenance, and
can reconstitute the dermis during wound healing.
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ΔNp63+

Figure 2: The stratified interfollicular epidermis: structure, cell types, and
regulatory genes. Stratification of the epidermis is dependent on complex
interactions between basal stem cells and transit amplifying cells (TACs) present in
the basal layer. These cells adhere to the basement membrane via interactions
between α6β4 and α3β1 integrins and laminin-5. Fibroblasts present in the dermis
secrete growth factors that diffuse across the basement membrane and promote the
proliferation and survival of basal keratinocytes. Basal stem cells and TACs divide
and migrate apically, and begin the process of differentiation, resulting in the
characteristic layers of the epidermis.
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(This figure is reproduced from Hsu Y.C., Li L., Fuchs E. Emerging interactions
between skin stem cells and their niches. Nature Medicine. 2014; 20(8):847-856
(36), with permission from Copyright Clearance Center).
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1.2.2. p63 isoforms in epithelial development and homeostasis
Epidermal development and homeostasis are tightly regulated by the transcription
factor p63, through its ability to coordinately regulate multiple transcriptional
programs involved in keratinocyte survival, replication, and differentiation (15, 23,
55). The importance of p63 in this process is highlighted by the fact that p63-null
(Trp63-/-) mice fail to develop a stratified epithelium, and exhibit perinatal lethality
due to desiccation and dehydration (
Appendix 1) (21, 23). Trp63-/- mice also exhibit incomplete limb development and
craniofacial malformations due to the inability to form the embryonic apical
ectodermal ridge. This structure relies on coordinated epithelial-mesenchymal
interactions, and is essential for limb and facial development. Notably, a number of
human ectodermal dysplastic syndromes are frequently caused by mutations in the
human p63 gene (56).
p63 expression is first detected prior to epidermal stratification around E8.5.
Isoform-specific RT-PCR analysis has demonstrated that the ΔNp63 isoforms are
the most abundant isoform expressed in the epidermis during all stages of
embryonic development (57). Conversely, TAp63 expression is first detected at E13,
and accounts for approximately 1% of all p63 mRNA expressed in the epidermis (58,
59). ΔNp63α is the predominant isoform expressed in basal keratinocytes, however
its expression is diminished in the differentiated suprabasal layers of the epidermis
(Figure 2 and Figure 3) (60-63). The specific role of p63 in epidermal development
and maintenance has been somewhat controversial, considering slight differences in
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the epidermal phenotypes of the Trp63-/- mice developed in the Roop (tm1Brd) (23)
and Mckeon (tm1Fmc) (21) laboratories (
Appendix 1). Specifically, the p63-knockout mouse developed in the Mckeon
laboratory Trp63-/- (tm1Fmc) contains small regions in the skin that exhibit features
of differentiation, including the expression of filaggrin, involucrin, and loricrin. This
led to the hypothesis that p63 is not required for epidermal differentiation, but rather
is necessary for the proliferation and survival of basal stem cells. Alternatively, the
p63-knockout mouse developed in the Roop laboratory Trp63-/- (tm1Brd) showed a
complete lack of epidermal differentiation markers, suggesting that p63 is absolutely
essential for epidermal stratification and development. Despite these differences, it
was clear that p63 plays an essential role in the proper development and function of
the epidermis. Neither model however could could determine which of the particular
p63 isoform(s) regulate these processes.
Using a transgenic strategy, the Melino laboratory demonstrated that ΔNp63
overexpression in the basal layer of Trp63-/- mice (Trp63-/-; ΔN) almost completely
rescued the epidermal phenotypes observed in p63-null mice, resulting in a
significant basal layer showing evidence of stratification (64). Alternatively, TAp63
overexpression in the same compartment (Trp63-/-; TA) showed no difference with
Trp63-/- mice (64). Instead, overexpression of both ΔNp63 and TAp63 isoforms in the
basal layer resulted in a near full epithelialization of the epidermis, compared to
either isoform alone. These conclusions are supported by the fact that isoformspecific deletion of ΔNp63 in mice (ΔNp63-/-) exhibit significant defects in epidermal
stratification and differentiation (29, 65). These results suggest that ΔNp63 essential
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for epithelial development and stratification, whereas the function of TAp63 may be
limited to terminal differentiation.
These hypotheses are further supported by subsequent observations, which
showed that ΔNp63 and TAp63 have non-overlapping transcriptional targets related
to epidermal development and differentiation. Specifically, ΔNp63 promotes the
expression of KRT14 (64), and is required for maintaining the replicative potential of
basal keratinocytes. ΔNp63 also binds to the promoters of p21WAF1/Cip1 and 14-3-3
and inhibits their transcription. This activity may account for the significantly reduced
proliferation observed in Trp63-/- keratinocytes (32). ΔNp63 has also been shown to
exhibit an antagonistic relationship with Notch signaling in the basal epidermis.
Specifically, ΔNp63 negatively regulates the expression of Hes-1 (66), an important
downstream mediator of Notch1 (67). Conversely, Notch1 inhibits the expression of
p63 through suppression of the interferon signaling pathway. The complex crosstalk
between p63 and Notch signaling is essential for the stratification and proper
functioning of the epidermis.
Alternatively, TAp63 induces the expression of Ets1, involucrin, K1, and K10,
each of which are involved in terminal differentiation of epidermal keratinocytes (64).
Taken together, these studies support the notion that ΔNp63 contributes to the
proliferation and stratification of basal keratinocytes, whereas TAp63 plays a minor
role in terminal differentiation.
While TAp63 is expressed at very low levels in the epidermis and has a
limited role in terminal differentiation, studies from our laboratory have nevertheless
implicated TAp63 as a critical factor in skin homeostasis and regeneration. These
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observations were made using TAp63 knockout mice, which were generated in our
laboratory (TAp63-/- (tm1.1Elrf)) (Appendix 2) (14). While TAp63-/- mice develop a
normal epidermis, they exhibit skin blisters, premature aging, and reduced wound
healing. In addition, TAp63-/- mice have reduced hair follicle morphogenesis. This led
to the discovery that TAp63 plays a critical role in maintaining a hair follicle stem cell
compartment known as skin-derived precursors (SKPs) (14, 53, 54). Notably, it was
discovered that TAp63 is the predominant isoform expressed in SKP cells (Figure 3).
TAp63 was found to transcriptionally regulate the cyclin-dependent kinase inhibitor
p57Kip2, which, in turn, maintains SKP cells in a state of quiescence and prevents
their hyperproliferation and premature senescence. In the absence of TAp63, SKP
cells are depleted in early adulthood, and this process accounts for the premature
aging phenotypes and skin defects observed in TAp63-/- mice.
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Figure 3: p63 isoforms are expressed in distinct stem cell compartments
within the interfollicular epidermis and hair follicle. ∆Np63 expression is
restricted to the basal epidermis, where it functions to maintain the proliferative
capacity,

self-renewal,

and

terminal

differentiation

of

basal

keratinocytes.

Alternatively, TAp63 expression is detected exclusively in a dermal stem population
present in the hair follicle, known as skin-derived precursors (SKPs). TAp63
maintains SKPs in quiescence, via transcriptional activation of CDKN1C (which
encodes p57).
(This figure is reproduced from Su X, Chakravarti D, Flores ER. p63 steps into the
limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev
Cancer. 2013; 13(2):136-43 (1) with permission from Copyright Clearance Center)
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1.3 p63 isoforms in squamous cell carcinomas (SCC)
1.3.1 Classical features of SCC
Squamous cell carcinomas (SCCs) are a common malignancy that occurs
throughout the human body in organs that are lined by a squamous epithelium.
These tumors frequently arise within the epithelium of the lung (LUSC), skin
(cuSCC), esophagus (ESCC), upper aerodigestive tract (HNSCC), and genitourinary
tract (68-74). These tumors share common characteristics that resemble normal
squamous epithelium, which has led to the hypothesis that all SCCs arise from
normal squamous epithelial cells. These cells line many organ surfaces throughout
the human body, and primarily serve as a barrier to the external environment. Due to
their location, squamous epithelial cells are frequently exposed to physical and
chemical insults. As a result, squamous-derived tumors are found to be primarily
driven by exposure to carcinogens, such as UV radiation, tobacco, or alcohol. To
protect the integrity of the tissue and the organism as a whole, squamous epithelium
has evolved a sophisticated pattern of cell turnover. This process relies on the
presence of long-lived stem cells and progenitors, which divide, differentiate, and
migrate in an apical or outward direction. This process creates the tight, protective
surfaces that define squamous epithelial tissues.
As squamous cells encounter genetic insults, they employ protective
mechanisms to prevent the accumulation of precancerous lesions and to protect the
integrity of the host tissue. These processes include, but are not limited to, cell cycle
arrest, DNA repair, terminal differentiation, and programmed cell death. Multiple
signaling pathways and transcriptional programs regulate each of these cellular
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processes. Understanding how these processes become disrupted during tumor
initiation and progression has led to breakthrough observations that may ultimately
inform and improve therapeutic interventions for squamous cell carcinomas.

1.3.2. Histological and clinical features of cutaneous squamous cell carcinoma
(cuSCC)
Non-melanoma skin cancer (NMSC), which primarily includes basal cell carcinoma
(BCC) and cutaneous squamous cell carcinoma (cuSCC), is the most common
malignancy diagnosed in the United States (75). Moreover, the global incidence of
NMSC continues to rise, with an estimated 3.5 million new diagnoses of skin cancer
each year (76). Fortunately, BCC rarely metastasizes and has a very high cure rate.
While primary cuSCC also has a high cure rate of about 95%, a subset of lesions fail
to respond to therapy, metastasize, and have a high rate of patient mortality (77).
While cuSCC accounts for approximately 20% of all NMSC lesions, this tumor type
accounts for the majority of NMSC-related metastatic death and disease (78). As a
result, cuSCC is one of the most costly cancers to treat in the United States (79).
Exposure to ultraviolet radiation (UVR) has been implicated as the primary
environmental risk factor for NMSC, including cuSCC (80). Elderly individuals with
pale complexions and a history of moderate chronic UV exposure have the highest
likelihood for developing cuSCC. On a molecular level, UVR induces specific
photochemical reactions that alter the chemical bonds of DNA, resulting in
characteristic DNA mutations. Such mutations are common in cuSCC and are
frequently observed in tumor suppressors such as NOTCH1 and p53 (81, 82).
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Additionally, UVR exposure can induce immune suppression in the skin, by
promoting the expression of immunosuppressive neuropeptides, cytokines, and
melanocortins (83).
BCC accounts for approximately 75% of all diagnosed NMSCs in
immunocompetent patients while cuSCC encompasses 20% of this tumor type.
Interestingly, however, these percentages are inverted in immunocompromised
patients (78). In fact, patients taking immunosuppressive drugs following organ
transplantation surgery exhibit a nearly 250-fold increase in developing cuSCC (84).
In addition to chronic immunosuppression, patients with a history radiation exposure,
or who have suffered from chronic skin wounding or burns, are at an elevated risk of
developing cuSCC (85).
Cutaneous SCC (cuSCC) encompasses a broad spectrum of histologically
diverse lesions, which display highly varied clinical outcomes. The current paradigm
for the development and progression of cuSCC includes a progression from normal
skin, to actinic keratosis (AK), to SCC in situ (SCCS), and finally, invasive SCC
(SCCI) (
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Table 1). While AK and SCCS exhibit minimal invasiveness and favorable
outcomes, a significant percentage of SCCI lesions fail to respond to therapy and
metastasize (86, 87). As with many other malignancies, the early detection and
treatment of high-risk tumors with an aggressive treatment regimen can result in
improved patient outcomes. As a result, the ability to identify and distinguish
between the stages of disease progression is critical in the clinical treatment of a
given tumor.
Actinic keratosis (AK) is a premalignant lesion that is generally accepted to be
the primary precursor to most cuSCC lesions (88). In line with the connection of
cuSCC to UV-exposure, AKs frequently develop on sun-exposed skin surfaces, such
as the head, neck, forearms, and back (89). Light-skinned individuals with a
propensity for sunburn are at the highest risk of developing AKs. Clinical
presentations of AK include scaly patches or papules, which are frequently red in
color, and are typically found in areas of the skin that exemplify other indications of
solar damage (90).
Histologically, AKs are restricted to epidermal foci that contain abnormal,
pleomorphic keratinocytes (91). These cells frequently exhibit nuclear atypia,
abnormal

keratinization,

and

the

loss

of

apical-basal

polarity.

Abnormal

keratinocytes within the basal layer frequently extend into the upper layers of the
epithelium, but by definition they do not span the full thickness of the epidermis.
The possible clinical outcomes for AKs include regression, persistence as an
identifiable AK, or progression into SCCS (92). The majority of AKs never progress
to bonafide cuSCC (93). However, the majority of cuSCC lesions are diagnosed in
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close physical association with AKs, leading to the hypothesis that AK is a direct
precursor to cuSCC (94).
SCCS (used interchangeably with ‘Bowen’s disease’) is typically diagnosed in
elderly patients (95) and, as is the case with AK, is most often found on the skin of
sun-exposed surfaces such as the face, neck, and hands (96). SCCS typically
presents as a slow growing erythematous scaly lesion, with an irregular border.
Such lesions may appear hyperkeratotic and ulcerated, and a small percentage will
appear pigmented (97). Most clinical studies have reported that a given SCCS lesion
has a risk of progression to SCCI of 3%–5% (98).
Histologically, the epidermis in SCCS will exhibit significant acanthosis with
elongation, in addition to an increase in the size of epithelial extensions into the
underlying dermis (i.e. rete ridges). SCCS lesions also frequently show features of
hyperkeratosis and parakeratosis, which are found above abnormal keratinocytes.
The majority of SCCS lesions will also frequently involve the interfollicular epithelium
and neighboring hair follicle and adnexal structures (86).
The conventional term “cutaneous SCC” typically refers to invasive squamous
cell carcinoma (SCCI). The observation that most SCCI lesions (>95%) are
associated with the malignant progression of an AK, has led to the general
consensus that AKs are the premalignant precursor for SCCI (99). SCCI shares
many histological features of AK and SCCS, however SCCI can be identified by the
presence of cells invading the basement membrane into the underlying dermis (90,
100). During the early stages of the disease, this invasion may be difficult to detect
histologically. However, the presence of atypical structures and keratinocytes
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through the full length of the epidermis may enable a diagnosis of SCCI (101). In late
stage SCCI, large pockets of abnormal tumor cells may be present in the underlying
dermis, in addition to infiltrating inflammatory cells.
SCCI can be subgrouped into three histologic grades depending on the
associated degree of nuclear atypia and the extent of keratinocyte differentiation.
The most common of the three subtypes is referred to as well differentiated SCCI,
which is characterized histologically by large, hyperchromatic nuclei, along with
extensive keratin production, which typically presents as atypical structures known
as keratin pearls (91). These tumors however will maintain intercellular bridges and
will have a very low probability of metastasis. On the other end of the spectrum are
poorly differentiated SCCI, which is characterized by significantly enlarged, atypical
nuclei and multiple mitotic figures. The most obvious distinguishing characteristic of
poorly differentiated SCCI is reduced keratin production. While these tumors are far
less common than the well-differentiated type, they harbor an enhanced risk for
recurrence and metastasis, and are typically found on the ear and lip (77). The third
and final subtype is moderately differentiated SCCI, which as its name suggests, is
characterized by features of both well- and poorly-differentiated SCCI.
Retrospective studies have shown that a given cuSCC lesion has an
estimated 4% risk of metastasis and an estimated death rate of about 2% (102). The
majority of metastatic spread is identified in nearby lymph nodes, however cuSCC
infrequently metastasize to more distant organs, including but not limited to the
brain, liver, and lungs (103-105). One of the most important determinants for
diagnosing and predicting the malignant potential for a given cuSCC lesion is its
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individual histological features. Additionally, however, are other factors that
demonstrate clinical utility when evaluating the risk for a given tumor. Several clinical
studies have demonstrated that the following characteristics are highly informative
when assessing risk of metastatic spread: differentiation status, anatomical location,
tumor diameter, immunosuppression, and perineural/perivascular invasion (102,
106-108).
Tumors located on the lip or the ear tend to have a very poor prognosis,
particularly SCCI with a poorly differentiated histology (77). Nevertheless, most
metastatic tumors will be well differentiated SCCI. Therefore it is essential to
examine other important clinical features as well (77). Another highly informative
prognostic characteristic is the size of the tumor and how deeply it has invaded into
the underlying dermis (77). In general, tumors with a diameter of more than 2 cm
have a high likelihood for recurrence and metastasis, whereas those with smaller
sizes have a significantly reduced risk of progression (109). The presence of
perineural and perivascular spread is also indicative of high-risk cuSCC. Another
clinical feature to be assessed is the presence of immunosuppression in the patient
harboring the tumor, as this can significantly increase the likelihood of cuSCC
development and progression (110, 111). Possible causes of immunosuppression
include the use of immunosuppressive drugs following transplant surgery, the
presence of a secondary cancer, and infection with HIV. Moreover, cuSCC lesions in
the context of immunosuppression tend to exhibit an elevated capacity for
metastasis

(112),

leading

to

significantly

immunocompromised patients (85).
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higher

mortality

rates

in

The primary treatment for most cuSCC lesions is surgical excision as it has
been shown to have a cure rate of 95% (113). The primary benefit for excisional
surgery is that it enables the histological examination of the tumor and the
surrounding skin tissue. Depending on the stage of disease, a surrounding margin of
normal skin will be removed (4-6 mm for low-risk and 6-10 mm for high-risk cuSCC)
(114,

115).

These

tissue

samples

are

subsequently

examined

by

a

dermatopathologist to determine if the entire tumor was successfully removed.
Mohs micrographic surgery (MMS) describes a commonly used surgical
technique that allows a detailed microscopic examination of excised tumor tissue. As
a result, MMS enables a more precise assessment of the tumor margins, thereby
improving the likelihood of total tumor removal, which is essential for minimizing
tumor recurrence. Due to the success of this technique, MMS has become the
primary treatment option for high-risk cuSCC (116).
Radiation therapy has been the non-surgical treatment of choice in cases of
cuSCC where patients are poor candidates for surgical treatments (e.g. tumors are
inoperable based on anatomical location). While it is highly effective for cuSCC
(particularly low-risk tumors), it entails a long treatment schedule and it does not
allow for extensive histological examination of the treated lesion. In addition there
are significant side effects of radiation therapy including but not limited to nausea,
malaise, and treatment-induced malignancies (117). Given these drawbacks,
radiation therapy alone is only used in cases where surgery is not feasible or when
other therapeutic options have failed (118).
The current treatment recommendation for high-risk cuSCC consists of
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adjuvant treatments including radiation therapy, due to the enhanced risk of tumor
recurrence and metastasis (119). Several options for adjuvant therapies to surgery
exist, however there is no consensus regarding the proper management of high-risk
cuSCC (120). As a result, more clinical research is required to correctly identify the
most efficacious therapy modalities.
Current efforts to improve the outcome of patients harboring high-risk cuSCC
include development of targeted molecular therapies. This includes the epidermal
growth factor receptor (EGFR), which is frequently overexpressed in many SCC
subtypes and has been shown to be essential for driving tumor cell survival and
proliferation (121, 122). Multiple therapeutic agents inhibiting EGFR or its
downstream signaling pathways have been identified, including the small molecule
tyrosine kinase inhibitors such as erlotinib and gefitinib and the monoclonal antibody
cetuximab (123). EGFR targeting has shown some clinical benefit in recent clinical
trials, however these observations are limited to a small and poorly defined subset of
cuSCC patients (124, 125). Therefore, further characterization of the underlying
molecular and genetic characteristics of high-risk cuSCC is necessary to identify
other pathways to target therapeutically.
Field cancerization is a concept that refers to an area of tissue that is
significantly altered and primed for malignancy due to exposure to carcinogenic
insults (126). Field cancerization in the skin is typified by the presence of multiple
AKs, SCCS, and SCCI, and is typically the result of UVR exposure (127). After these
primary lesions are treated, clinical focus typically shifts towards treating the
surrounding region of potentially damaged skin. One way of addressing field
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cancerization in the context of actinically-damaged skin includes topical medications
such as ingenol mebutate and fluorouracil, which function by clearing the skin of
potentially premalignant epithelial cells (128). Another option shown to exhibit
significant preventative benefits is photodynamic therapy, which includes the use of
a photosensitizer such as methyl aminolevulinate (MAL), visible light exposure, and
reactive oxygen species to similarly clear the tissue of cancerized cells (126, 129).
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Table 1: Clinical and histological features of the cuSCC spectrum of disease.
Normal skin
•

Well-defined epidermal

Actinic Keratosis (AK)
•

layers
•

Normal keratinocytes

•

Scaly patches or

•

•

Atypical structures and

with irregular borders and

keratinocytes through the full

Abnormal,

possible ulceration

length of the epidermis

pleomorphic

mitotic figures

keratinocytes
restricted to epidermal

•

Significant acanthosis with

•

possible hyperkeratosis
•

May involve adjacent

Invasion of tumor cells into
the underlying dermis

•

Varying degrees of

foci

follicular and adnexal

differentiation, with poorly

Atypical keratinocytes

structures

differentiated lesions as

3%–5% risk of progression

having higher risk for

to SCCI

recurrence and metastasis.

do not span full length

•

of epidermis
•

Scaly erythematous lesions,

Invasive SCC (SCCI)

papules

with low number of

•

SCC in situ (SCCS)

Minimal risk for
malignant progression
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1.3.3. Genomic and molecular features of cutaneous squamous cell carcinoma
The advent of improved and cost effective high throughput genetic and molecular
technologies has made it possible to comprehensively characterize thousands of
human patient tumors. Large-scale research consortiums that leverage these
technologies along with relevant clinical data have been established in order to
identify the common genetic and epigenetic traits of human cancer. The Cancer
Genome Atlas (TCGA) Research Network is one of the largest consortiums,
consisting of 20 collaborating institutions in the United States and Canada. Since its
inception in 2005, it has generated a comprehensive characterization of over 11,000
patient tumors, consisting of 33 different pathologically defined tumor types. This
massive collection of data has become an invaluable resource for researchers and
clinicians, and has led to several important observations with regards to the
underlying biology of human tumors.
Interestingly, a recent cross-platform analysis of 12 different cancer types led
to the observation that several common genetic and molecular features are shared,
not only within the same tumor type, but also across divergent, pathologically distinct
cancers as well (73). One of the most striking findings was the convergence, based
on genetic and molecularly defined similarities of LUSC, HNSCC, and some bladder
cancers (BLCA). Using an unbiased approach, Hoadley et al demonstrated that
these tumors, which they termed C2-Squamous like, shared significant overlap with
regards to specific gene mutations, copy number alterations (CNAs), and gene
expression patterns (73). The specific alterations in C2-squamous like tumors
included TP53 mutations, TP63 and SOX2 amplification, as well as hyperactivation
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of cell proliferation and immune pathways (73). Interestingly, many of these same
genetic aberrations are also seen in human SCCs arising in other tissues, including
esophageal SCC (ESCC) (130), cuSCC (72, 131), and cervical squamous cell
carcinoma (CESCC) (132). The convergence of SCCs in terms of their underlying
genetics suggest that targeted therapies discovered to be effective in one SCC
subtype may prove to be effective for the treatment of multiple SCC subtypes.
As of this publication, cuSCC has not been included in TCGA. However,
similar efforts to provide a comprehensive molecular and genetic characterization of
cuSCC have been made. In one such study, Pickering et al. investigated aggressive
cuSCC using exome sequencing of DNA from frozen tumors and matched normal
blood form 39 patients (131). Strikingly, they found a mutation rate of 61.2
mutations/Mb, which is one of the highest mutation rates amongst human cancers,
including LUSC and HNSCC (133). Previous studies have found that inactivation of
TP53, CDKN2A, NOTCH1 and NOTCH2 are common genetic alterations in cuSCC
(134-140). Similarly, Pickering et al. found that nine of the most commonly mutated
genes, including TP53 (94.9%), CDKN2A (43.6%), NOTCH1 (59.0%), HRAS
(20.5%), CASP8 (23.1%), AJUBA (17.9%), RASA1 (12.8%), FAT1 (43.6%), and
KMT2D (69.2%), are also commonly mutated in HPV-negative HNSCC and LUSC
(131).
RNA sequencing (RNA-seq) of UV-driven mouse and human patient skin
(NS), actinic keratosis/papillomas (AK/PAP), and cuSCC identified the dysregulation
of multiple pathways, which may be relevant to disease progression (72). For
example, it was found that β-catenin/Wnt signaling is activated throughout the
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progression of cuSCC (72). In addition, the transcriptional targets of AP1 are
downregulated across the progression of cuSCC, indicating that epidermal
differentiation is disrupted in cuSCC (141). This conclusion is further supported by
the preponderance of mutations in genes involved in NOTCH signaling in cuSCC
tumors (72, 131, 137, 142, 143). In addition, transcriptional drivers of cuSCC,
including NFY, E2F, and ELK1 were found to be activated early in tumor
development (e.g. during the NS to AK/PAP transition), whereas MYC-dependent
transcriptional programs are activated in the progression of AK/PAP to cuSCC.
Pathway analysis of differentially expressed genes of both mouse and human
cuSCC showed enrichment for pathways related to the DNA damage response, cell
cycle progression, and mitotic roles of polo-like kinase (72).
These transcriptional changes were frequently associated with recurrent
CNAs, which resemble those observed in both HNSCC and LUSC. These include
chromosomal gains of 3q and 8q, and the loss of chromosomes 5q, 8p, and 18 (70,
71, 131). Gain of 3q is of particular interest due to the fact that this region harbors
PI3KCA, SOX2, and TP63, each of which have been shown to exhibit oncogenic
roles in cuSCC and other tumors (1, 144, 145). Targeted sequencing of 29 human
cuSCC lesions found that ~24% of tumors showed specific amplification of TP63,
however they did not find amplification of PIK3CA or SOX2 (143). This suggests that
TP63 overexpression is the critical factor that favors the amplification of 3q in
cuSCC. Importantly, ΔNp63 isoforms are typically overexpressed, whereas TAp63
isoforms are lost or underexpressed (31, 61). Studies in mice show that cuSCC
tumors rely on the expression of p63, as the inhibition or deletion of p63 results in
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apoptosis and cuSCC regression (31, 146). Conversely, decreased expression of
TAp63 promotes the formation of metastatic sarcomas and carcinomas, including
cuSCC (147). These observations support the notion that ΔNp63 isoforms function
as oncogenes in cuSCC, whereas TAp63 isoforms function as tumor suppressors.
The disruption of normal miRNA expression has been causally linked to the
pathogenesis of many tumor types (148, 149), including cuSCC (72, 150, 151).
Using functional pair analysis, which relies on miRNA-mRNA targeting predictions,
Chitsazzadeh et al. found that miRNAs 15a/b, 17, 20a, 21, 31, 200a and 340b were
frequently overexpressed in cuSCC (72). Likewise, miR-21 and miR-31 have been
previously shown to be causally linked to the development and progression of
tumors, including cuSCC (152-154). Conversely, miRNAs 30a, 125b, and members
of the let-7 family were found to be significantly downregulated in cuSCC tumors
(72).
Taken together, these observations suggest that cuSCC exhibits distinctive
molecular and genetic characteristics, many of which overlap with SCCs that arise in
other tissues, most notably HNSCC and LUSC. These include mutations in TP53,
CDKN2A, FAT1/2, CASP8, and NOTCH, chromosomal CNAs involving 3q, 5p, and
8p, and aberrant mRNA and miRNA expression of genes related to squamous
differentiation, epithelial-to-mesenchymal transition, cell cycle progression, and DNA
damage responses.
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1.3.4. Regulation of miRNA expression and biogenesis
miRNAs are a class of evolutionally conserved non-coding RNAs that ~20-24 nt in
length. They are found in most organisms, including plants, animals, and protists
(155). The primary function of miRNAs is to repress mRNA stability and translation.
This occurs through Argonaute-mediated binding to specific mRNAs by binding to
partially complementary sequences in the 3’ UTR, and, albeit less frequently, the
coding sequence (CDS), or 5’ UTR of target mRNAs (156). Depending on the
degree of complementarity between the miRNA and mRNA, the miRNA-Argonaute
complexes suppress translation or can induce mRNA decay.
miRNA genes are transcribed by RNA polymerase II into long precursor
transcripts known as pri-miRNAs (Figure 4) (157). Following transcription, the
majority of pri-miRNAs are spliced, capped, polyadenylated, and cleaved by a
protein complex known as the Microprocessor (158-160). This complex includes
DGCR8 and the RNAse III enzyme Drosha. The Microprocessor cleaves pri-miRNAs
into shorter hairpin RNAs, which are referred to as pre-miRNAs. The pre-miRNA
forms a complex with XPO5 and RAN-GTP, which facilitates the nuclear export of
the pre-miRNA into the cytoplasm (161, 162). This process requires the hydrolysis of
GTP, which also results in the disassembly of the complex and the release of the
pre-miRNA.
In the cytoplasm, pre-miRNAs are cleaved by another RNAse III-type
endonuclease known as Dicer (Figure 4) (163-165). Dicer cleaves the pre-miRNA
near the terminal loop, resulting in a short RNA duplex. This duplex then binds
argonaute (AGO) proteins and TRBP to form a functional RNA:protein complex
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known as the RNA-induced silencing complex (RISC) (166, 167). After loading, the
RNA duplex unwinds and one of the strands (referred to as the passenger strand, or
miRNA*) is ejected from the RISC complex. Typically, the miRNA strand with the
less stable 5’ terminus is preferentially selected to function as the guide strand in the
mature RISC complex (168, 169). Once released from RISC, the passenger strand
is degraded. Importantly, strand selection may vary in different cellular contexts.
Occasionally the passenger strand can be favored, and exert its inhibitory functions
on target genes that are typically mutually exclusive of the targets of the
corresponding guide strand (153, 170).

1.3.5. Regulation of miRNAs by the p53 family in epithelial development and
cuSCC
The p53 family of transcription factors has been shown to play an essential
regulatory role in miRNA expression and processing (Figure 4) (29, 147, 171, 172).
Conversely, p53, p63, and p73 are themselves targets of specific miRNAs, indicating
a complex interaction between p53, p63, p73 and miRNA expression. Recent
studies have implicated this network in normal epithelial development and
tumorigenesis.
miRNAs play an important role in normal skin development and homeostasis.
Multiple studies have implicated miRNA expression in keratinocyte differentiation
and epidermal development. This is exemplified by the fact that the disruption of
miRNA expression and processing results in severe defects in epidermal
stratification. Notably, miR-203 has been shown to be a critical regulator of ∆Np63,
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specifically by restricting its expression to the basal layer of the epidermis (18, 173).
Transgenic expression of miR-203 in the basal layer of the epidermis results in
perinatal lethality due to incomplete epidermal development and significantly
reduced expression of ∆Np63. These phenotypes mimic the phenotypes observed in
∆Np63-/- mice (29), demonstrating the strong inhibitory effect of miR-203 on ∆Np63
expression in the epidermis. It was found that miR-203 expression induces cell cycle
arrest and significantly reduces the self-renewal capabilities of basal keratinocytes.
These effects were dependent on the suppression of ∆Np63, as well as the inhibition
of Skp2 and Msi2 (18). Through this regulation, miR-203 was found to be a critical
regulator of epidermal stratification.
Conversely, ∆Np63 itself is a regulator of miRNA expression through its ability
to transactivate DGCR8, which is an important component of the Microprocessor
complex (Figure 4). This regulation mediates the downstream biogenesis of select
miRNAs, which have been found to be important in regulating epithelial homeostasis
stemness (29). Importantly, disruption of this regulatory axis has been linked to the
pathogenesis and progression of cuSCC (33). In fact, our laboratory has found that
targeting ∆Np63 and DGCR8-dependent miRNAs, including miR-128 and let-7d, can
be an effective therapeutic strategy in treating cuSCC.
While ∆Np63 functions through DGCR8, our laboratory has shown that TAp63
is a potent transactivator of Dicer transcription, and therefore a global regulator of
miRNA biogenesis and expression (Figure 4) (147). These observations are
noteworthy, as TAp63 isoforms have also been implicated in skin homeostasis and
regeneration, albeit in a different stem cell compartment. The TAp63-/- (tm1.1Elrf)
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mice generated in the Flores lab exhibit premature aging phenotypes that were most
pronounced in the skin of adult mice (14) (Appendix 2). It was discovered that the
loss of TAp63 results in the hyperproliferation and subsequent premature
senescence of hair follicle stem cells, known as SKP cells. Interestingly, genomewide miRNA profiling of senescent and proliferative human keratinocytes found that
miRNA expression is significantly dysregulated in senescent keratinocytes (174,
175). Whether or not TAp63-mediated mIRNA expression plays a role in the
senescence of keratinocytes or SKP cells remains to be explored.
Interestingly, recent studies have found that TAp63-/- (tm1.1Elrf) mice develop
a number of metastatic carcinomas and sarcomas, including cuSCC (Appendix 2)
(147). Of particular significance, it was found that decreased expression of miRNAs
was responsible, in part, for TAp63-mediated tumor suppression. This coincides with
the observation that miRNA expression is frequently reduced in human cancers,
suggesting that most miRNAs exert tumor suppressive functions (176, 177). In
addition, components of the miRNA biogenesis pathway, including Dicer, are also
frequently mutated or expressed at low levels (178-180). Taken together, these
studies show that TAp63 exerts tumor suppression in part through the regulation of
miRNAs. The specific miRNAs involved in these processes, however, remain to be
identified and characterized.
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Figure 4: Regulation of miRNA biogenesis by p53 family members.
Dysregulation of miRNA expression has been implicated in the pathogenesis of
human cancer. In general, expression of miRNAs and members of the miRNA
biogenesis pathway is reduced in human patient tumors. Notably, these
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observations coincide with mutations or downregulation of p53 family members.
Indeed, functional experiments have implicated p53, TAp63, and ΔNp63 in the
expression of miRNAs and miRNA biogenesis. Both p53 and TAp63 have been
shown to directly promote transcription of miRNA genes. Further, TAp63 regulates
the transcription of Dicer, and this regulation has been shown to be important for
tumor suppression. Mutant p53 has been shown to inhibit TAp63-mediated
transcriptional activation of Dicer, which enhances the invasive capacity of tumor
cells. Interestingly, ΔNp63 has been found to promote miRNA biogenesis through
the transcriptional activation of DGCR8.
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1.4. p73 and tumorigenesis
1.4.1 Tumor suppressive functions of TAp73
The p53 family member p73 was discovered in the late nineties along with p63
(181). Similar to p63, p73 is expressed as multiple isoforms, due to the occurrence
of alternative splicing, and the presence of two alternative promoters (Figure 1).
There are at least 6 isoforms that are expressed in humans, and they are generally
grouped into 2 primary classes of p73 isoforms, depending on the presence or
absence of the N-terminal acidic transactivation domain (TA). Isoforms expressed
from the upstream 5’ promoter are typically referred to as TAp73, whereas the
isoforms expressed from the downstream 3’ promoter are known as ∆Np73. TAp73
isoforms structurally resemble p53 and TAp63, and therefore mimic many of their
transcriptional functions (24). ∆Np73 isoforms, which lack the TA domain, have been
shown to inhibit the transcriptional activity of p53 and TAp73 (182). As a result, the
general paradigm is that TAp73 exerts tumor suppressive functions, similar to TAp63
and p53, whereas ∆Np73 isoforms exhibit oncogenic potential.
To ascertain the physiological functions of p73, the Mckeon laboratory
generated the fist p73 knockout mouse (Trp73-/-) (
Appendix 1) (183). In contrast to Trp53-/- or Trp63-/- mice, Trp73-/- mice show
reduced body size, and exhibit neurological defects, highlighting a critical function for
p73 in neurogenesis. In addition, the majority of the Trp73-/- mice die from chronic
infections, including rhinitis, otitis, perioorbital oedema, and conjunctivitis, around 4-5
weeks of age (183, 184). This observation suggested that p73 isoforms play a role
regulating proper immune development. Subsequent studies found that p73-deficient
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mice are also tumor prone, supporting the notion that p73 functions as a tumor
suppressor (
Appendix 1) (184). In fact, 60% of Trp73-/- mice that survive into late
adulthood develop LUAC. Interestingly, Trp73+/- mice are also tumor prone,
developing both LUAC (10%), as well as thymic lymphomas (12.5%) and
hemangiosarcomas (12.5%) (
Appendix 1). These observations suggest that p73 is a haploinsufficient tumor
suppressor. Taken together, these early studies indicated that p73 isoforms played
critical roles in the development of the immune system and the central nervous
system, as well as in tumorigenesis. Unfortunately, however, these early studies
using total p73-knockout mice precluded the possibility of attributing any of these
functions to a specific isoform.
Early studies into the specific functions of each p73 isoform suggested that
TAp73 and ∆Np73, in general, have opposing functions (24, 182). Specifically, it was
found that TAp73 is capable of inducing cell cycle arrest and apoptosis, mimicking
many of the canonical tumor suppressive functions of p53 and TAp63 (24). The
tumor suppressive functions of TAp73 were confirmed in vivo, as TAp73 knockout
mice (TAp73-/- (tm1Mak)) were found to be tumor prone (Appendix 2) (185, 186).
Specifically, TAp73-/- mice develop lymphoma, LUAC, and colon carcinoma. These
mice also exhibit hippocampal dysgenesis, suggesting that TAp73 may be at least
partially responsible for the neurological defects observed in Trp73-/- mice (183).
Moreover, TAp73-/- mice show evidence of premature aging, and shorter lifespans.
These phenotypes may be caused by genomic instability, which has been observed
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in multiple cell types of TAp73-/- mice. Likewise, it has been hypothesized that the
increased genomic instability may also contribute to the increased tumor phenotype
of TAp73-/- mice. Indeed, subsequent studies have shown that DNA damage
stabilizes the TAp73 protein, through direct interaction with the DNA mismatch repair
protein PMS2 (187). In turn, it was found that TAp73 transcriptionally activates DNA
repair genes, including MUYTH, SMUG1 (188), Mre11, RAD51, and BRCA2 (4).
Studies have also shown that TAp73 can facilitate cell cycle arrest in both G1 and
G2/M through the transcriptional activation of p21 or GADD45 (189, 190). TAp73 is
also capable of inducing mitochondria-dependent apoptosis via transcriptional
activation of BAD, BAX, BIK, NOXA, and PUMA (191, 192). Taken together these
studies led many to conclude that TAp73 functions as a tumor suppressor, with
specific functions that overlap with p53 and TAp63, as well as unique and tissue
specific functions.

1.4.2. Genomic and molecular features of lung adenocarcinoma
Lung cancer is the number one cause of cancer-related deaths worldwide (193,
194). Non-small cell lung cancer (NSCLC), which includes lung squamous cell
carcinoma (LUSC) and lung adenocarcinoma (LUAC), accounts for approximately
85% of all lung cancer cases. LUAC is the most common subtype of NSCLC and is
responsible for nearly one million deaths per year, making it the deadliest cancer
worldwide (195). In recent years, molecularly targeted therapies have improved
survival for patients whose tumors express mutated oncogenes, including EGFR and
ALK (196, 197). Unfortunately, the majority of LUAC tumors lack an identifiable
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driver mutation that can be treated with molecularly targeted therapy. Instead, LUAC
tumors frequently exhibit activating KRAS mutations and/or mutations in tumor
suppressor genes, such as TP53, KEAP1, STK11, RB1, and CDKN2A (198).
Attempts to target KRAS or reactivate mutant tumor suppressors as therapeutic
strategies have largely failed. As a result, the majority of LUAC patients are treated
with conventional chemotherapy, albeit with limited success.
The therapeutic application of antibodies that target the programmed death-1
(PD-1)-programmed death-ligand (PD-L1) immune checkpoint pathways has
resulted in significant improvements cancer treatment outcomes (199), including for
patients with NSCLC (200). This is due to the intrinsic capacity of endogenous
cytotoxic CD8+ T cells to eliminate cancer cells (201, 202), which can lead to tumor
regression and improved survival (203, 204). Clinical studies have shown however,
that the effectiveness of checkpoint blockade immunotherapy is limited to a subset
of patients. Therefore, a major goal of recent clinical research has been focused on
understanding the mechanisms that dictate the effectiveness of immune checkpoint
inhibitors. This research has shown that the presence of tumor-infiltrating T cells is a
predictor for responsiveness to these therapies (205). Understanding the
mechanisms that regulate T cell infiltration and activity may lead to new therapeutic
strategies that may increase the number of patients who benefit from checkpoint
blockade immunotherapies.

1.4.3. Modeling lung adenocarcinoma in the mouse
Genetically engineered mouse models (GEMM) are particularly useful as they allow
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cancer researchers to study different aspects of tumorigenesis in a genetically
distinct system, in the natural microenvironment of a given tumor type. This allows
cancer researchers to more accurately investigate the potential contribution of a
given genetic mutation to the development and/or progression of a particular cancer.
In addition, autochthonous tumor models allow researchers to investigate non-cell
autonomous mechanisms that act on tumor development, including the effect of the
tumor microenvironment and the immune system.
To better understand the fundamental biology and genetics of LUAC, multiple
groups set out to develop preclinical animal models that faithfully recapitulate the
features of the human disease. The most commonly used mouse models of LUAC
contain conditional alleles for oncogenic Kras (206, 207) and/or conditional deletion
of p53 (208), which are the two most frequently mutated genes in human LUAC
(198). The oncogenic KrasLSL-G12D/+ mouse developed in the laboratory of Tyler Jacks
is frequently used in such studies (206-211). The intratracheal delivery of replicationdeficient viral vectors expressing Cre recombinase induces recombination in the
lung cells of the trachea, bronchioles and distal lung. The conditional expression of
the oncogenic KrasG12D mutant protein is sufficient to induce lung adenomas in
mice in as little as 2 weeks (206). The combination of KrasLSL-G12D/+ with other
conditional alleles (such as mutant p53) (208, 211) has been shown to significantly
accelerate tumor development and progression, resulting in tumors that are highly
invasive and metastatic.
To monitor tumor development and progression in a systematic and
quantifiable way, the laboratory of Tyler Jacks developed a 4-stage system of
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grading tumors that develop in these models (208, 209). The earliest lesions, which
encompass atypical adenomatous hyperplasias (AAH) and small adenomas, feature
uniform (e.g. normal) nuclei, and are thus designated at Grade 1 lesions. Grade 2
adenomas are larger in size, and contain nuclei that are enlarged and exhibit
prominent nucleoli. Bona fide adenocarcinomas resembling human lesions are
designated as Grade 3 lesions. These tumors exhibit a higher degree of pleomorphic
nuclei, conspicuous nucleoli, and nuclear molding. Grade 4 adenocarcinomas exhibit
similar cellular characteristics as Grade 3 lesions, along with a higher mitotic index,
tumor giant cells, an invasive stromal reaction, and invasive edges along blood
vessels and/or the pleura.
Together these model systems are incredibly useful for preclinical studies of
the underlying mechanisms that drive the development and progression of LUAC.
Ultimately, the conclusions drawn from such studies have a high probability of
informing the development of newer, more effective therapies for LUAC.
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Figure 5: Modeling lung adenocarcinoma in the mouse. (A) The oncogenic
KrasLSLG12D mouse allele generated in the Jacks lab. (B) Anesthetized mice are
aligned onto a platform with their teeth across a thin metal bar, such that the head,
neck, and chest are positioned perpendicular to the base of the platform, allowing
effective insertion of a catheter into the trachea. Adenovirus suspended in media is
administered into the catheter and is inhaled by the mouse (C and E) Representative
H&E stainings (C) and tissue segmentation (E) of lung sections from TAp73fltd/fltd;
KrasLSLG12D/+

mice 30 weeks after intratracheal adenovirus infection. (E-H)
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Representative images of oncogenic KrasG12D-driven lung tumors, including grade 1
(E), grade 2 (F), grade 3 (G), and grade 4 (H) tumors.
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Chapter 2: Materials and Methods
Content of this chapter is partly based on the following article:
Martin-Lopez M, Maeso-Alonso L, Fuertes-Alvarez S, Balboa D, Rodríguez-Cortez
V, Weltner J, Diez-Prieto I, Davis A, Wu Y, Otonkoski T, Flores ER, Menéndez P,
Marques M, and Marin MC. p73 is required for appropriate BMP-induced
mesenchymal-to-epithelial transition during somatic cell reprogramming. Cell Death
and Disease (2017) 8(9), e3034.

2.1 Animal studies
Mouse studies were approved by the IACUC at the University of Texas MD
Anderson Cancer Center or the IACUC at Moffitt Cancer Center. TAp63fl/fl and
TAp63-/- mice were generated previously (14). TAp63-/- mice (14) were backcrossed
over 10 generations to generate TAp63-/- and WT mice on a pure C57BL/6
background. Athymic nu/nu mice were purchased from Envigo. SOX2-CreER (212),
RosamT/mG (213) were purchased from JAX labs. The KrasLSLG12D (214) mouse was a
gift from Jonathan M. Kurie. Age- and sex-matched mice were used for all
experiments, unless noted otherwise.

2.2 Generating the TAp73fltd/fltd and TAp73∆td/∆td mice
The cre-loxP strategy was used to generate the TAp73 conditional knockout reporter
allele (TAp73fltd). Genomic DNA encompassing the Trp73 locus from intron 1 to
intron 3 was amplified from mouse genomic DNA (C57BL/6). A neomycin resistance
gene (neo) flanked by frt sites was inserted in intron 3. LoxP sites were cloned into
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the endogenous locus upstream (5’) to exon 2 and downstream (3') of the frt-flanked
neo cassette. tdTomato was cloned upstream of the 5' loxP site in an antisense
orientation, while the synthetic CAG promoter was cloned, in an antisense
orientation, downstream of the 3' loxP site. The modified p73 locus was cloned into
the pL253 plasmid vector (215). Mouse embryonic stem cells (G4) electroporated
with the targeting vector were analysed by Southern blot analysis for proper
targeting of the TAp73fltd allele. Resulting chimaeras were mated with C57BL/6
albino females and genotyped as described below. Mice with germline transmission
of the targeted allele (TAp73fltd) were intercrossed to generate homozygous mice
(TAp73fltd/fltd).
TAp73fltd/fltd

Total knockout mice (TAp73∆td/∆td) were generated by crossing
mice

with

transgenic

mice

expressing

an

oocyte-specific

cre

recombinase (Zp3-Cre) (216). TAp73fltd/+; Zp3-Cre mice were intercrossed to
generate TAp73fltd/∆td; Zp3-Cre mice, which were subsequently intercrossed to
generate TAp73∆td/∆td mice.

2.3 4-hydroxytamoxifen (4OHT) treatment of mice
To induce recombination in the SOX2+ skin-derived precursor (SKP) cell
compartment, 3 week old SOX2CreER/+; RosamT/mG; TAp63+l+ and SOX2CreER/+;
RosamT/mG; TAp63fl/fl mice were shaved on their dorsal side, and treated with 3
consecutive days of 1mg 4OHT (Sigma; H6278) diluted in ethanol at 5mg/ml via
topical administration to the back skin.
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2.4 UVR treatments
To model UVR-driven cuSCC, 4-week-old mice were shaved on the entire dorsum
prior to irradiation, and as needed throughout the experiment. Mice were exposed to
low-dose UVR (2.5kJ m-2, 3x a week) using a bank of 4 FS40 T12 fluorescent
sunlamps (Westinghouse, NJ). Control mice were regularly shaved but not exposed
to UVB. Mice were irradiated for up to 60 weeks or until tumors exceeding 2mm in
diameter developed, at which point the mice were euthanized and the tissues were
collected for RNA extraction and/or histological processing.

2.5 Tumor xenograft studies
To model human cuSCC, we modified the use of a previously described xenograft
model of cuSCC (217). COLO16 cells stably expressing RFP and luciferase were
reverse transfected with miRNA mimics or scrambled mimic control. Six hours later,
the transfected cells were harvested and diluted in a 1:1 mixture of PBS and matrigel
(Corning). 2 x 105 COLO16 cells transfected with either miRNA mimic were
subcutaneously injected into one side of 6-week-old female athymic nu/nu mice. The
side of injection was randomized such that the each mouse received an injection of
cells transfected with miRNA mimic on one side, while the other flank was injected
with cells transfected with the scrambled control mimic. Tumor growth was
measured with calipers and tumor volume was calculated using the following
formula: tumor volume (mm3) = (D x d2) / 2, where D and d are the longest and the
shortest diameters of the tumor, respectively. In parallel, tumor growth was
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monitored using bioluminescence imaging of luciferase activity using a Bruker In
Vivo Xtreme Imaging system. 3 mg of D-luciferin (GoldBio) was administered to
each mouse via intraperitoneal injection, 6 minutes prior to bioluminescence
imaging. Radiance (photons/sec/cm2/steridian) was determined within a consistent
region that encompassed each flank of all imaged mice using the Molecular Imaging
Software “MI” version 7.2.0 (Bruker). Mice were euthanized when the biggest tumors
of the respective controls were 1,000mm3, or if the mice exhibited symptoms of
distress.

2.6 Intratracheal adenoviral infections
Intratracheal administration of viral particles was carried out as described previously
(209,

214).

Briefly,

8-to-10

week

old

mice

were

anesthetized

using

xylazine/ketamine and were intratracheally infected with 2.5 x107 or 7.5 x107 Pfu of
adenovirus expressing Cre (Ad5-CMV-Cre) or empty vector (Ad5-CMV-empty) coprecipitated with CaCl2 suspended in 50 microliters (µl) of minimum essential media
(MEM).

Infected mice were kept on a heating pad and monitored until

consciousness was fully regained.

2.7 Histology
Mouse tissues were harvested and fixed in 10% neutral-buffered formalin, and
embedded in paraffin. Assistance in processing murine tissue samples was provided
by the MD Anderson Research Histopathology Facility or the Moffitt Cancer Center
Tissue Core Histology Core. Five-micron (µm) sections were cut from formalin-fixed,
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paraffin-embedded (FFPE) skin and tumors and de-waxed in xylene and re-hydrated
using decreasing concentrations of ethanol. FFPE samples were stained with
hematoxylin and eosin, using standard protocols, or were used for immunostaining
purposes.

2.8 Immunohistochemistry of murine skin and cuSCC
Five-micron (µm) sections were cut from formalin-fixed, paraffin-embedded (FFPE)
skin and tumors and de-waxed in xylene, followed by re-hydration in decreasing
concentrations of ethanol. Antigens were unmasked using citrate buffer unmasking
solution (Vector Laboratories) and samples were subsequently incubated in blocking
solution for one hour at room temperature. Primary antibody incubation was
performed overnight at 4°C with the following primary antibodies: cytokeratin 5
(1:1000) (Abcam ab53121). Visualization was performed using ImmPRESS
secondary antibodies (Vector Laboratories) and the ImmPact DAB peroxidase
substrate kit (SK4100, Vector Laboratories). Immunostained slides were then
counterstained with hematoxylin, dehydrated, and mounted following standard
protocols. Images were acquired using an Olympus IX83 microscope or Zeiss
Imager 2, and analyzed using the CellSens Dimensions software or Zeiss Zen
software. Alternatively, bright field images were acquired using an Aperio™
Scanscope AT2 digital whole slide scanner (Leica). Tumor pathology was
characterized with the assistance of Kenneth Y. Tsai, M.D.
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2.9 Immunohistochemistry for lung tissues
Five-micron (µm) sections were cut from formalin-fixed, paraffin-embedded (FFPE)
tissues and were stained using the Ventana Discovery XT automated system and
associated

proprietary

reagents

(Ventana

Medical

Systems)

as

per

the

manufacturer's protocol. Slides were deparaffinized using the EZ Prep solution
(Ventana Medical Systems) and the heat-induced antigen retrieval method was used
in Cell Conditioning 1 Mild (Ventana Medical Systems). The following antibodies
were used: rabbit anti-CD31, (1:200; #ab28364, Abcam), rabbit anti-CD3 (1:100;
M307, Spring Biosciences), and rabbit anti-CD11b, (1:700; #LS-C141892, Lifespan
Bioscience). All primary antibodies were diluted in Dako antibody diluent and
incubated for 32 minutes. The Ventana ChromoMap kit was used for detection.
Immunostained slides were then counterstained with hematoxylin, dehydrated, and
mounted following standard protocols.

2.10 Double-staining immunohistochemistry for CD4/CD8 on lung tissues
Five-micron (µm) sections were cut from formalin-fixed, paraffin-embedded (FFPE)
tissues and were stained using the Ventana Discovery XT automated system and
associated proprietary reagents (Ventana Medical Systems, Tucson, AZ) as per the
manufacturer's protocol using. Slides were deparaffinized using the EZ Prep solution
(Ventana) and heat-induced antigen retrieval method was used in Cell Conditioning
1 (Ventana). Primary rabbit anti-CD8 (#98941, Cell Signaling, Danvers, MA) was
incubated for 60 min. Slides were incubated with the Ventana OmniMap anti-rabbit
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secondary Antibody for 16 min and detected with the Ventana ChromoMap DAB kit.
Subsequently, the slides were incubated for 32 minutes with rabbit anti-CD4
(#50134-R001, Sino Biological, Wayne, PA).

Slides were incubated with the

Ventana UltraMap Anti-rabbit secondary antibody for 16 minutes with ChromoMap
Red detection. Immunostained slides were then counterstained with hematoxylin,
dehydrated, and mounted following standard protocols.

2.11 Immunofluorescence
Paraffin embedded tissue sections were prepared as described previously (184).
Sections were incubated with rabbit anti-SOX2 (EPR3131, Abcam, 1:100), chicken
anti-GFP (ab13970, Abcam, 1:200), guinea pig anti-Cytokeratin 14 (LS-C22637,
LifeSpan Biosciences, 1:500). For secondary antibodies, AlexaFluor 568 goat antirabbit (703-545-155, Life Technologies, 1:500), Alexa Fluor 633 goat anti-guinea pig
(A-21105, Life Technologies) or Alexa Fluor 488 goat anti-chicken (A-11039, Life
Technologies) antibodies were used. Slides were mounted with coverslips and
Vectashield® Hardset™ Mounting media with DAPI (H-1500).

2.12 Imaging and lung tumor segmentation
H&E stainings of FFPE tissue sections were scanned using the Aperio™ ScanScope
AT2 (Leica Biosystems, Vista, CA) with a 200x/0.8NA objective lens. These images
and their meta-data were then imported into the Definiens Tissue Studio v4.2 suite
or Visiopharm v 7.2 for segmentation analysis. A machine-learning algorithm was
used to segment each tissue section image into "tumor", "alveoli", "normal", and
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"background". Segmentation was further refined using size, shape, and proximity
classifiers. This refinement step was necessary to correct regions that were
misclassified during the initial learning iterations. Data features to determine the
number of tumors and percent tumor area were extracted from the final
segmentation. In addition to the tumor level segmentation each cell (nucleus and
cytoplasm) within each tumor was segmented and identified for future analysis
considerations.

2.13 Generating mouse embryonic fibroblasts (MEFs)
WT and TAp73∆td /∆td mouse embryonic fibroblasts (MEFs) were generated as
described previously (24).

2.14 Cell culture
Human cutaneous squamous cell carcinoma (cuSCC) cell lines (COLO16 and
SRB12) were kindly provided by Dr. K.Y. Tsai. Normal human epidermal
keratinocytes (NHEKs) were purchased from Lonza. All cuSCC cell lines were
maintained in culture conditions as previously reported (218, 219). NHEKs were
cultured in KGM-GoldTM Keratinocyte Growth media (Lonza).

2.15 Lenti-virus infection
COLO16 and SRB12 cells were seeded at a density of 5 x 106 cells in 10-cm dishes
prior to infection. Approximately 16 hours later, cells were infected with lenti-rLV-
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EF1a-mCherry-Nuc-IRES-Puro-WPRE

(Vectalys™)

or

lenti-FLuc-T2A-RFP

(BioSETTIA), at a multiplicity of infection of 5 particles per cell, and supplemented
with polybrene (2µg/ml) for 24 hours. After infection, cells were subjected to 48
hours of puromycin (2µg/ml) selection, at which point transduction efficiency was
quantified by assessing mCherry or RFP-positive cells.

2.16 Reverse transfections
Cells were transfected with 55.5 nM hsa-miR-30c-2-3p (miRVana™ miRNA mimic,
ambion®,

MC12646),

hsa-miR-497

(miRVana™

miRNA

mimic,

ambion®,

MC10490), Negative Control (miRVana™ miRNA mimic, ambion®, 4464061),
siAURKA (MISSION® siRNA, Sigma, SASI_Hs01_00079240), siCDK6 (MISSION®
siRNA,

Sigma,

SASI_Hs01_0004879),

siFAT2

(MISSION®

siRNA,

Sigma,

SASI_Hs01_0033187), siORC1 (MISSION® siRNA, Sigma, SASI_Hs01_00038886),
siKIF18B

(MISSION®

siRNA,

Sigma,

SASI_Hs02_00314896),

siPKMYT1

(MISSION® siRNA, Sigma, SASI_Hs01_00199784), siORC1 (MISSION® siRNA,
Sigma, SASI_Hs01_00038886), siControl (MISSION® siRNA, Sigma, SIC001), or
siControl-Cy5 (MISSION® siRNA, Sigma, SIC005) using Lipofectamine® RNAiMAX
(Invitrogen™). The mixture of oligos and Lipofectamine were added to tissue culturetreated plates and incubated for 20 minutes, after which trypsinized cells were plated
on top. The effects on target gene levels were tested 48 hrs post transfection.
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2.17 RNA isolation
Tissue specimens were flash frozen in liquid nitrogen and homogenized with a
mortar and pestle and subsequently lysed in Qiazol reagent from the miRNeasy
RNA isolation kit (Qiagen). Total RNA was extracted according to the manufacturer’s
instructions. RNA concentration was determined by measuring the total absorbance
at 260nm using a Nanodrop™ 2000 spectrophotometer.

2.18 RNA sequencing and analysis
RNA sequencing (Illumina Hi-Seq) yielded 30–40 million read pairs for each sample.
The mRNA-Seq mouse sample reads were aligned onto the mouse genome build
UCSC mm10 (NCBI 38). The HTSeq software platform was used to quantify
overlaps between aligned sequence reads and annotated genomic features,
including genes and exons. The scaling factor method was used to normalize the
resulting counts.

2.19 Small RNA-seq analysis
Illumina small RNA adapter sequences were removed from sequence reads. Reads
shorter than 10 nt or ending in homopolymers greater than or equal to 9 nt were
discarded. From this, the total number of usable reads for each sample was
calculated. Sequence reads were then mapped to the miRBase (220) reference
(http://www.mirbase.org/) using BLAST. The relative abundance of each individual
miRNA sequenced in the experiment was counted as a fraction of the total usable
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reads

(parts

per

million).

The

ComBat

normalization

algorithm

(221)

(http://www.bu.edu/jlab/wp-assets/ComBat/ Abstract.html) was used to minimize
potential batch effects. Differentially expressed miRNA were identified following a
cut-off of absolute fold-change greater than 1.5, and a p value less 0.05 (t-test) using
the R statistics software. Principal Component Analysis (PCA) was used to examine
sample clustering.

2.20 miRNA-mRNA Functional Pair Analysis
We evaluated the enrichment of miRNA–mRNA pairs using the SigTerms
methodology (222). Briefly, a one-sided Fisher exact test was applied along with
microRNA target predictions using TargetScan (223) to determine the miRNAs for
which its predicted gene targets are significantly enriched (false discovery rateadjusted q less than 0.25; fold-change greater than 1.25) in a given gene signature.
Finally, we determined the conserved miRNAs enriched the mouse TAp63-/- cuSCC
signature, as well as the human cuSCC signature. Enriched microRNA–mRNA pairs
were visualized using the Cytoscape software (http://www.cytoscape.org/).

2.21 RT-qPCR
Total RNA from cells and tumors was used to synthesize complementry DNA using
the qScript™ XLT cDNA Synthesis Kit (QuantaBio) followed by qRT-PCR using the
PerfeCTa SYBR® Green SuperMix reagent (QuantaBio) according to the
manufacturer’s protocols. The following primers were used, as described previously:
histone H3 (224), TAp63 (225), and Dicer (226). Alternatively, gene expression was
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assessed using the qScript™ XLT One-Step RT-qPCR ToughMix, Low ROX kit
(QuantaBio) and TaqMan® assays (Applied Biosystems™). For human samples, the
following TaqMan® assays were used: POL2RA (Hs00172187_m1), GAPDH
(Hs03929097_g1), AURKA (Hs01582072_m1), CDK6 (Hs01026371_m1), FAT2
(Hs01087234_m1), ITGA6 (Hs01041011_m1), KIF18B (Hs00977735_m1), ORC1
(Hs01069758_m1), PKMYT1 (Hs00993620_m1), pri-miR-30c-2 (Hs03302833_pri),
and pri-miR-497 (Hs03303903_pri). For mouse samples, the following assays were
used: TAp73 (Mm00660223_m1), and Gapdh (Mm99999915_g1). qRT-PCR was
performed using an Applied Biosystems™ QuantStudio™ 6 Flex Real-Time PCR
System. Reactions were performed in triplicate and ΔΔCt values were calculated
using H3 (SYBR® Green), POL2RA (Taqman), or GAPDH (Taqman) as an internal
control.

2.22 miRNA Taqman Real Time qPCR assays
Expression of mature miRNAs was assessed using TaqMan® miRNA assays
(Applied Biosystems™). Total RNA (10ng per reaction) was used to synthesize
complementary DNA using the TaqMan® MicroRNA Reverse Transcription Kit
(Applied Biosystems™) and TaqMan® primers for the specific miRNAs being
assayed. The following assays from were used: hsa-miR-30c-2* (002110), hsa-miR497 (001043), mmu-miR-17* (002543), snoRNA234 (001234), and RNU6B (001093)
(Applied Biosystems™). qRT-PCR was performed using the TaqMan Universal
Master Mix II (no UNG) with TaqMan primers for the specific miRNAs and run on a
QuantStudio™ 6 Flex Real-Time PCR System (Applied Biosystems™). Reactions
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were performed in triplicate and ΔΔCt values were calculated using RNU6B (human
samples) or snoRNA234 (murine samples) as an internal control.

2.23 Western blot analysis
Fifty microgram (µg) of protein lysates were electrophoresed on a 6%, 8%, 10% or
12.5% SDS PAGE gel and transferred to nitrocellulose membranes as described
previously (147). High molecular weight proteins (e.g. FAT2) were transferred
(without ethanol) in a 70C water bath for 40min at 40V as described previously
(227). Blots were probed with anti-AURKA (1:1000) (ab13824, Abcam), anti-CDK6
(1:1000) (3136S, Cell Signaling), anti-FAT2 (1:100) (sc59985, Santa Cruz), antiITGA6 (1:500) (ab97760, Abcam), anti-ORC1 (1:100) (sc23887, Santa Cruz), antiPKMYT1 (1:1000) (ab134108, Abcam), or anti-TAp73 (A300-126A, Bethyl
laboratories) at 4 °C for appx. 18 hr, followed by incubation for 1 hr at room
temperature with the appropriate secondary antibodies conjugated to horseradish
peroxidase (1:5,000) (Jackson Lab), IRDye® 800CW (1:10,000) (LI-COR®), or
IRDye® 680LT (1:10,000) (LI-COR®). HSP90 (1:10,000) (ab13495, Abcam), mouse
β-Actin (1:5,000) (Sigma), and rabbit β-Actin (1:5,000) (Sigma) were used as loading
controls. ECLTM Prime reagent was used for chemiluminescent detection when HRPconjugated secondary antibodies were utilized. All Westerns were imaged using the
Odyssey® Fc imaging system (LiCOR®) and analyzed using the Image StudioTM
software (LiCOR®).
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2.24 Real time cell growth and apoptosis analysis
All proliferation and apoptosis imaging experiments were performed with the
IncuCyte ZOOM imaging platform (Essen Bioscience). Cells were plated at a density
of 5 x 103 cells per well. Experiments were conducted for 72-96 hours, with data
collection every 6 hours. Four planes of view were imaged per well of a 96-well plate
using a 10X objective. Images were collected in phase contrast, green fluorescence
(Ex: 440/80 nm; Em: 504/44 nm), and red fluorescence (Ex: 565/05 nm; Em: 625/05
nm) for all experiments. Spectral unmixing was set at 5% of red fluorescence
removed from the green channel. Processing definitions were developed for each
particular experiment, however the same processing definition was utilized for each
replicate experiment. For transfection experiments, cells were reverse transfected
using Lipofectamine® RNAiMax (Invitrogen) in suspension and plated at a density of
5 x 103 cells per well in 6 replicate wells of a 96-well plate. For drug treatment
experiments, cells were plated at 5 x 103 cell per well, and treated with the indicated
drugs 24 hours after plating, at which point the cells were imaged every 6 hours.
Cells were plated in media containing IncuCyte® Annexin V-AlexaFluor 488
Reagent (Essen Bioscience). Total cells were calculated based on the number of
nucRed-mCherry+-positive nuclei detected in each well. The percentage of apoptotic
cells was calculated for each time point by counting the number of overlapping green
(Annexin V+) and red (nucRed-mCherry+) cells and dividing it by the total number of
nuclei in each well. Cells were scanned 6 hours after transfection, and every 6 hours
thereafter.
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2.25 Edu incorporation assays
Cells were plated at a density of 5 x 104 cells in 6 replicates in a 96-well dish. Three
independent replicate experiments were performed for each assay. To evaluate cell
proliferation, the cells were pulse labeled for 3 hours with 10 mM EdU (5’-ethynyl-2’Apoptosis was monitored by incubating the cells with Annexin V-Alexa Fluor 488
(Essen BioScience) according to the manufacturer’s instructions. Total nuclei were
labeled using NucRed™ Dead 647 Readyprobes reagent. Images were captured
and percentage of edu-positive cells was quantified using the IncuCyte highthroughput plate reader and accompanying software (Essen Bioscience).

2.26 Cell migration and invasion assays
Cells were incubated for 2 hours with 4ug/ml of mitomycin C to arrest the cells. Cells
were trypsinized in resuspended in RPMI media without serum, and subsequently
plated in 6 replicate wells at 1 x 103 cells per well in an IncuCyte ClearView 96 well
cell migration plate (Essen BioScience), whose wells were either left uncoated (for
migration assays) or coated with 20 µL of 200 µg/mL growth factor reduced matrigel
(Corning®) (for invasion assays). RPMI media containing 10% horse serum was
added to the bottom chambers of each well to serve as a chemo-attractant. Images
of the top and bottom of each well were captured using the IncuCyte high-throughput
plate reader and accompanying software (Essen Bioscience). Cell migration and
invasion were quantified as the percentage of cell confluence on the bottom of each
well and was normalized to the initial confluence of cells on the top of each well
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2.27 Cell viability assays:
Cell viability was assessed in 96-well format using the CelltiterGlo® (Promega)
luminescence measured on a GloMax® Discover System plate reader (Promega)
according to the manufacturer’s instructions. Cell viability of drug treated cells was
calculated as a percentage of luminescence relative to the vehicle-treated cells.
Dose response parameters, including the half maximal inhibitory concentration
(IC50) were calculated using nonlinear regression using GraphPad Prism 7
software, based on the results from at least 3 independent experiments.

2.28 Cell cycle profiling using flow cytometry
Cells to be collected for cell cycle profiling were grown in 6cm TC-treated dishes.
Trypsinized cells were fixed in 1% formaldehyde (1X PBS) on ice for 15 minutes,
and subsequently post-fixed with ice-cold 80% ethanol for a minimum of 4 hours.
Fixed cells were pelleted and resuspended in 1mL of 0.25% Triton X-100 and
incubated on ice for 5 minutes. Cells were resuspended in 5mL of 1X PBS and
pelleted. Cell pellets were resuspended in 100uL of PBS containing 1% BSA and
0.5ug of rat anti-phospho-histone H3 (S28) (BD BioSciences; HTA28) or normal IgG,
and then incubated for 30 minutes at room temperature, in the dark, with gentle
agitation. Cell suspensions were then rinsed with an additional 5mL of 1X PBS plus
1% BSA and then pelleted. Cell pellets were then resuspended in 100ul of 1X PBS
containing 0.1% Triton X-100 and 1µg/ml DAPI and incubated in the dark for 20
minutes with gentle agitation. Cell cycle profiles were analyzed by flow cytometry
using a BS LSR II cell analyzer (BD Biosciences). The flow cytometer was set for UV

62

excitation (340-380nm wavelengths) and detection of DAPI emission at blue
wavelengths (450-495nm). DNA content was analyzed using the ModFit LT V3.3.11
software, whereas phospho-H3 staining was analyzed using FCS express 6 plus
(DeNovo Software). Different cell populations were quantified based on DNA content
to discern cells with 2N (G1), 2-4N (S), and 4N (G2/M). The percentage of cells in
G2 was determined by subtracting the percentage of mitotic cells (e.g. the phosphoH3-positive population) from the G2/M population as determined by DNA content
measurements.

2.29 Sample Preparation for Proteomics
Cells were lysed in denaturing lysis buffer containing 8M urea, 20 mM HEPES (pH
8), 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate and 1 mM βglycerophosphate. A Bradford assay was carried out to determine the protein
concentration. Equal amount of heavy and light proteins were mixed together. The
mixed proteins were reduced with 4.5 mM DTT and alkylated with 10 mM
iodoacetamide. Trypsin digestion was carried out at room temperature overnight.
Tryptic peptides were acidified with 1% trifluoroacetic acid (TFA) and desalted with
C18 Sep-Pak cartridges according to the manufacturer’s protocol.

2.30 TMT Labeling
100 microgram of peptide from each sample was labeled with TMT reagent. LCMS/MS and spectral counting was used to analyze the incorporation of the TMT
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label. 98% or greater label incorporation was achieved for each channel. The 6
samples were then pooled and lyophilized.

2.31 High pH Reversed Phase Peptide Separation
After lyophilization, the peptides were re-dissolved in 400 micro liter of 20 mM
Ammonium Formate, (pH 10.0). The high pH reversed phase separation was
performed on a Xbridge 4.6 mm x 100 mm column packed with BEH C18 resin, 3.5
µm, 130Å. (Waters) The peptides were eluted as follows: 5% B (5 mM Ammonium
Formate, 90% acetonitrile, pH 10.0) for 10 minutes, 5% - 15% B in 5 minutes, 1540% B in 47 minutes, 40-100% B in 5 minutes and 100% B held for 10 minutes,
followed by re-equilibration at 1% B. The flow rate was 0.6 ml/min, and 24
concatenated fractions were collected. Speedvac centrifuge was used to dry the
peptides.

2.32 Liquid chromatography-tandem mass spectrometry
A nanoflow ultra high performance liquid chromatograph (RSLC, Dionex) coupled to
an electrospray bench top orbitrap mass spectrometer (Q-Exactive plus, Thermo)
was used for tandem mass spectrometry peptide sequencing experiments. Samples
were first loaded onto a pre-column (2 cm x 100 µm ID packed with C18 reversedphase resin, 5µm, 100Å) and washed for 8 minutes with aqueous 2% acetonitrile
and 0.04% trifluoroacetic acid. Trapped peptides were eluted onto an analytical
column, (C18, 75 µm ID x 25 cm, 2 µm, 100Å, Dionex). A 90-minute gradient was
programmed as follows: 95% solvent A (2% acetonitrile + 0.1% formic acid) for 8
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minutes, solvent B (90% acetonitrile + 0.1% formic acid) from 5% to 38.5% in 60
minutes, then solvent B from 50% to 90% B in 7 minutes and held at 90% for 5
minutes, followed by solvent B from 90% to 5% in 1 minute and re-equilibrated for 10
minutes. The flow rate on the analytical column was 300 nl/min. Sixteen tandem
mass spectra were collected in a data-dependent manner following each survey
scan. Both MS and MS/MS scans were performed in Orbitrap to obtain accurate
mass measurement using a 15 second exclusion for previously sampled peptide
peaks.

2.33 Data Analysis
MaxQuant (version 1.5.2.8) (228) was used to quantify the TMT reporter ion
intensities.

2.34 Human cytokine antibody array
Relative cytokine levels in conditioned media (CM) were determined using the
Human Cytokine Antibody Array C5 (RayBiotech®) according to the manufacturer’s
instructions. Chemiluminescent detection was performed using the Odyssey® Fc
imaging system and was quantified using the associated ImageStudio software (LiCOR®). Following background subtraction, the relative levels of individual cytokines
present in CM were normalized based on the relative intensities of the positive
control spots.
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CHAPTER 3: UNDERSTANDING THE REGULATION OF MIRNAS BY TAP63 IN
CUTANEOUS SQUAMOUS CELL CARCINOMA
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Chapter 3: Understanding the regulation of miRNAs by TAp63 in cutaneous
squamous cell carcinoma
3.1. Introduction and rationale
Cutaneous squamous cell carcinoma (cuSCC) is the second most common cancer
type diagnosed in the United States, with an estimated incidence of 700,000 new
cases each year (76). Cumulative exposure to ultraviolet radiation (UVR) is the most
common environmental risk factor for the development of cuSCC, in part through its
ability to induce mutagenesis in the skin epithelium. The most effective course of
treatment for cuSCC is surgical excision, which is occasionally accompanied with
adjuvant radiotherapy (113, 119). While the management of cuSCC generally has a
favorable outcome, there is a small but significant percentage of patients, whose
lesions fail to respond to therapy, resulting in severe morbidity and reduced survival.
Efforts to develop more effective targeted therapies for treatment-resistant cuSCC
have largely been unsuccessful. A better understanding of the underlying genetic
and molecular determinants of cuSCC will likely facilitate the development of more
effective treatments.
miRNAs are a class of small, highly conserved non-coding RNAs that have been
shown to have significant roles in many different biological processes and cellular
contexts. Interestingly, studies have shown that they are frequently disrupted in
disease states, including cancer (229). The primary function of miRNAs is to inhibit
the translation of mRNAs, via direct interaction between miRNAs and specific
mRNAs via Watson-Crick base pairing between nucleotides 2-7 of the miRNA and
complementary

sequences

in

targeted
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mRNAs

(156).

Consequentially,

understanding the functions of a given miRNA depends upon identifying the mRNAs
that it targets, which may be numerous, and may also be cell- and context-specific
(230).
Large percentages of cuSCC (72, 131), as well as squamous cell cancers of the
lung (LUSC), head and neck (HNSCC), esophagus (ESCC), and bladder (BSCC)
share mutations in TP53, along with overexpression of TP63 and de-regulated
miRNA expression (70, 71, 73, 231). Our lab and others have shown that TP63
encodes a diverse group of p63 isoforms, including TAp63 and ΔNp63, which exhibit
non-overlapping and even antagonistic functions (1). ΔNp63 isoforms have been
shown to promote tumor cell survival (31), whereas the downregulation of TAp63
isoforms is sufficient to initiate tumor development and promote metastasis (147).
Notably, both TAp63-/- and TAp63+/- mice are highly susceptible to spontaneous
sarcoma and carcinoma development, including cuSCC (147). Mechanistic studies
found that TAp63 directly transactivates the expression of primary miRNA transcripts
encoding miR-130b and miR-34a, as well as Dicer, an endoribonuclease that
cleaves pre-miRNAs into short double-stranded RNA fragments called miRNAs. In
addition, we found that ΔNp63 isoforms can affect miRNA expression through
transactivation of DGCR8, another critical component of the miRNA biogenesis
pathway (29). DGCR8 binds to Drosha in the nucleus to form the Microprocessor
complex, which cleaves primary miRNA transcripts (pri-miR) into precursor miRNA
(pre-miR) molecules (158, 159), which are transported out of the nucleus into the
cytoplasm, where Dicer subsequently processes it into functional mature miRNAs.
Interestingly, ΔNp63-mediated regulation of DGCR8 and downstream miRNAs,
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including let-7d and miR-128, are necessary for the viability and proliferative
potential of cuSCC (33). Together, these studies describe critical functions for both
ΔNp63 and TAp63 in the regulation of miRNA expression in tumorigenesis.
Given these observations we set out to investigate the mechanisms through
which TAp63 regulates miRNA expression in UVR-induced skin carcinogenesis. Our
results show that TAp63-deficient mice develop UVR-driven cuSCC at a significantly
higher rate compared to wild-type (WT) mice. Through the use of next generation
sequencing, we identified several miRNAs whose expression are deregulated in
TAp63-/- tissues, most notably miR-30c-2* and miR-497. We also found that several
predicted

and

verified

mRNA

targets

of

these

miRNAs

are

conversely

overexpressed in human cuSCC. Reintroduction of miR-30c-2* and miR-497, or
inhibition of their validated targets was sufficient to halt tumor cell proliferation and
survival. Among these targets, we found that the miR-497 target AURKA was
frequently overexpressed in cuSCC, and was associated with poor survival in
patients with HNSCC. Moreover, inhibition of AURKA was effective at suppressing
cuSCC proliferation and inducing cell death. Thus, we propose that dysregulation of
these miRNAs and their downstream targets promote tumor development and
progression.

3.2 Results
3.2.1. Loss of TAp63 promotes UVR-induced tumorigenesis
To investigate the role of TAp63 in skin tumorigenesis, we first compared UVRinduced tumor formation among mice with normal TAp63 (WT) and homozygous
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deletion of TAp63 (TAp63-/-) (14) (Figure 6A). As anticipated, this treatment induced
cutaneous tumors in both cohorts, including pre-malignant papillomas and fully
malignant cuSCC (Figure 6B and Figure 6E). While the number of papillomas did not
differ between the two genotypes, we observed a higher frequency of cuSCC in the
TAp63-/- cohort (Figure 6C-D). These results suggest that the loss of TAp63
promotes malignant progression.
An important prognostic feature of cuSCC is differentiation status. Tumors
with a poorly differentiated histology harbor an enhanced risk for recurrence and
metastasis (77). Close histopathological examination found that all of the identified
tumors, regardless of genotype, were well-differentiated cuSCC, indicating that the
loss of TAp63 does not impact primary tumor differentiation (Figure 6E). Since we
have previously shown that TAp63-deficient mice are prone to metastatic
tumorigenesis (147), we examined the organs of irradiated mice for evidence of
metastasis. While no metastases were found in WT mice, multiple lung
micrometastases, which stained positive for the squamous cell marker keratin 5,
were found in one of the TAp63-/- mice bearing cuSCC lesions (data not shown).
Taken together, these results indicate that TAp63 may be an essential tumorsuppressor in UVR-induced cuSCC.
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Figure 6: Loss of TAp63 promotes UVR-induced tumorigenesis. (A) WT and
TAp63-/- mice were aged with or without chronic UVR (5kJ/m2, 3x a week, for up to
60 weeks) and subsequently analyzed for tumor development. (B) Gross pathology
images of chronically irradiated mice. White arrowheads indicate the presence of
cuSCC

tumors.

(C)

Quantification

of

the

percentage

of

mice

harboring

histopathologically-verified cuSCC lesions for both genotypes. (D) The average
number of pre-malignant papillomas and cuSCCs per mouse were quantified for
each genotype. * p<0.05, two-tailed t test. (E) Representative H&E stainings of welldifferentiated cuSCC tumors from the indicated genotypes. Keratin pearls (black
arrow) indicate squamous differentiation.
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3.2.2. Lineage tracing SOX2-positive stem cells during cuSCC development
Our laboratory previously demonstrated an essential role for TAp63 in preventing the
hyperproliferation of a SOX2-positive stem cell population referred to as skin-derived
precursors (SKPs) (14). In addition, recent studies in mice have shown that SOX2
plays a critical role in tumor initiation and tumor maintenance, and may function as a
master regulator of cancer stemness (232, 233). Given the enhanced UVR-induced
cuSCC phenotype of TAp63-/- mice, we asked whether SKPs may be a cell of origin
for cutaneous SCC. To address this question we first immunostained WT and
TAp63-/- skin and cuSCC for the expression of SOX2. As expected, SOX expression
was limited to the dermal papilla (DP) and dermal sheath (DS) of anagen hair
follicles (data not shown) (14). Consistent with previous reports however, we found
that SOX2 was expressed in a small but significant fraction of both WT and TAp63-/cuSCC tumors (Figure 7A). Notably, this expression was most frequently observed
along the tumor-stroma interface, which has been shown to be highly enriched for
cells with high tumor-initiating potential (234, 235). We did not however see a
significant difference in the percentage of SOX2-positive cells across the two
genotypes. These results suggest that our UVR-induced cuSCC model produces
tumors that express SOX2, similar to what has been observed previously in
chemically-induced mouse models of cuSCC (232, 233).
While previous studies have shown that SOX2-expressing cells have
significantly increased tumor initiating potential, it remains to be determined if
cuSCC tumors develop from a SOX2-expessing cell in the skin. Alternatively, it
remains possible that cuSCC originates in a SOX2-negative cell (e.g. basal
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keratinocytes) and acquires the capacity for de novo SOX2 expression during tumor
progression. To definitively evaluate the capacity SOX2-positive skin cells to serve
as cancer initiating cells, I have designed and initiated a lineage tracing experiment
combined with our UVR-induced cuSCC model (Figure 7B). Mice bearing a
tamoxifen-inducible CreER knocked into the SOX2 locus (Sox2CreER/+) (212) were
intercrossed with mice expressing a conditional fluorescent reporter (RosamT/mG)
(213). These mice were then intercrossed with mice harboring the TAp63 conditional
knockout allele (14). This genetic strategy enables SOX2-specific recombination of
the fluorescent reporter, thus permanently labeling cells originating from SOX2specific cells in the skin (e.g. SKP cells). The presence or absence of the TAp63
conditional knockout allele also allows us to address whether or not the loss of
TAp63, specifically in the SOX2-positive SKP cell compartment, accounts for the
increased susceptibility of cuSCC development in TAp63-/- mice.
To verify specific recombination of the reporter allele in SOX2-positive SKP
cells, mice bearing the above genotypes were treated at post-natal day 21 with
topical 4-hydroxytamoxifen (4OHT) or ethanol for 3 consecutive days. As expected,
nuclear SOX2 expression was detected in the nuclei of DP cells in anagen hair
follicles (Figure 7D). Importantly, GFP expression was restricted to DP cells of
Sox2CreER/+; TAp63fl/fl; RosamT/mG and Sox2CreER/+; TAp63+/+; RosamT/mG mice treated
with 4OHT. Conversely, mice treated with ethanol, or Sox2+/+; RosamT/mG; TAp63fl/fl
mice did not show GFP expression.
After verifying the efficiency and accuracy of the reporter strategy, we
generated mice bearing the following genotypes: 1) Sox2+/+; RosamT/mG; TAp63fl/fl 2)
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Sox2CreER/+; RosamT/mG; TAp63+/+ and 3) Sox2CreER/+; RosamT/mG; TAp63fl/fl (Figure
7C). These mice were then treated at post-natal day 21 with topical 4hydroxytamoxifen (4OHT) or ethanol for 3 consecutive days. On p24 or p25, the
treated mice were subjected to chronic solar-simulated UVR-treatment (5kJ/m2, 3x a
week). As of the date of this publication, we have analyzed a subset of the irradiated
cohort. Interestingly, we have detected multiple GFP-positive hair follicles in a
Sox2CreER/+; RosamT/mG; TAp63fl/fl mouse after 43 weeks of irradiation (Figure 7E). We
also identified a cuSCC tumor from this mouse that contained a significant
population of SOX2-positive cells (Figure 7F and Figure 7G). This tumor was GFPnegative however, suggesting that it did not arise from a GFP-positive SKP cell. We
are currently in the process of finishing these irradiations at which point we will fully
analyze each tumor for SOX2 and GFP expression.
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development. (A) Representative merged immunofluorescence images of WT and
TAp63-/- murine cuSCC sections immunostained for K14 (red) and SOX2 (green),
and counterstained with DAPI (cyan). (B) Alleles included in the lineage tracing
experiment. The RosamTmG allele harbors an inducible fluorescent reporter knocked
into the Rosa26 locus. Unrecombined cells constitutively express tdTomato,
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however following cre-mediated recombination, tdTomato and a stop codono are
excised enabling expression of the GFP allele. The SOX2-CreER allele harbors cre
recombinase conjugated to an estrogen-receptor domain (CreER), which requires
the binding of tamoxifen to translocate into the nucleus, thus enabling
recombination. Mice will also have WT TAp63, or the floxed TAp63 (TAp63fl) allele
as shown. Cre-mediated recombination of this allele deletes exon 2, and therefore
the expression of TAp63 isoforms. (C) Experimental design for the lineage tracing
experiment. Mice bearing the indicated genotypes, were treated with 1mg 4OHT for
3 consecutive days. On the fourth day, these mice were subjected to chronic UVR
treatment, 3x per week, and analyzed for intratumoral expression of GFP or
tdTomato. (D-F) Representative confocal microscopy images of longitudinal sections
of mouse hair follicles from P24 mice with the indicated genotypes following 3
consecutive days of 200ul with vehicle (ethanol) or 5mg/ml 4-hydroxytamoxifen
(4OHT). SOX2 expression is restricted to the cells in the dermal papilla (DP) (red).
GFP expression (green) is restricted to SOX2-expressing cells in SOX2CreER/+;
TAp63fl/fl; RosamT/mG mice treated with 4OHT. Right panels show SOX2-positive (red,
arrows) and EGFP-positive (green, arrowheads) DP cells at higher magnification. (EG) Representative merged immunofluorescence images of skin (E) and tumor
sections (F and G) from Sox2CreER/+; TAp63fl/fl; RosamTmG mice treated with 4OHT,
followed by 43 weeks of UVR exposure. Sections were immunostained for K14
(magenta), GFP (green), and SOX2 (red), and counterstained with DAPI (cyan).

76

3.2.3.

TAp63-deficient

tumors

exhibit

deregulated

mRNA

and

miRNA

expression
Since TAp63 has been implicated in miRNA biogenesis (147), we asked whether the
increase in cuSCC development was due to the dysregulation of miRNA expression
in the skin. To answer this question, we performed RNA-seq and small RNA-seq on
skin and histologically verifiable cuSCC lesions from both WT and TAp63-/- irradiated
mice. In total, 3 WT normal skin, 3 TAp63-/- normal skin, 2 WT cuSCC tumors, and 3
TAp63-/- cuSCC tumor samples were sequenced and analyzed. Principal component
analysis (PCA) of samples based on the differentially expressed mRNAs (Figure 8A)
showed that the global expression pattern distinguished skin from cuSCC samples.
Moreover, we found that the samples within each tissue type grouped according to
genotype, indicating that the loss of TAp63 may have global effects on the
transcriptional landscape of normal skin and cuSCC. Unsupervised hierarchical
clustering of mRNAs (Figure 9A) and miRNAs (Figure 9B) also showed clustering of
normal skin and cuSCC samples, however the samples did not perfectly segregate
according to genotype within each tissue type. Taken together these results suggest
that the loss of TAp63 affects a significant proportion of the cuSCC transcriptome.
To identify TAp63-regulated mRNAs and miRNA networks, we generated a
TAp63-/- cuSCC signature from the mRNA (Figure 8B) and miRNA (Figure 8C)
expression datasets (fold change > 1.5, p-value <0.05). To identify those targets that
are dependent on TAp63, we focused on genes and miRNAs that were differentially
expressed in the TAp63-/- cuSCC signatures but were not similarly affected in WT
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cuSCC (Figure 8D, blue). From this comparison we identified 1993 mRNA and 90
miRNAs that were differentially expressed in the TAp63-/- cuSCC signature.
In order to examine the possibility that TAp63-regulated miRNAs are
functional in the pathogenesis of cuSCC, we performed miRNA-mRNA pair analysis
by identifying differentially expressed miRNAs that complement miRNA response
elements (MREs) within the 3’ UTR of significantly anti-correlated mRNAs via
Watson-Crick base pairing (222, 236). Functional pairs were identified within the
TAp63-/- SCC signature and integrated network maps were generated to identify key
miRNA-mRNA pairs that were associated with loss of TAp63 in cuSCC (Figure 10
and Figure 11). Altogether, the TAp63-/- cuSCC signature contained 28
underexpressed miRNAs with 311 overexpressed mRNAs (Figure 10), and 25
overexpressed miRNAs with 333 underexpressed mRNAs (Figure 11).
To determine if any of the TAp63-associated miRNAs and mRNAs are
conserved in human cuSCC, we compared the TAp63-/- cuSCC signature to
previously published human cuSCC mRNA and miRNA signatures generated from 9
cuSCC and 7 normal skin samples obtained from human patients (72) (Figure 8D).
This comparison identified 263 mRNAs (93 upregulated, 170 downregulated) and 13
miRNAs (8 upregulated, 5 downregulated) (Appendix 3) that were differentially
expressed in both mouse TAp63-/- cuSCC and human cuSCC. Gene set enrichment
analysis (GSEA) revealed significant deregulation of genes in pathways related to
the regulation of cell proliferation and cell death (Figure 8E). Both of these
processes are identified as hallmarks of human cancer (237, 238). Moreover,
previous studies have demonstrated that TAp63 is a transcriptional regulator of
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protein coding genes involved in these two processes (2, 14, 24), and that this
regulation is a major component of the tumor suppressive functions of TAp63. Prior
to this study, however the role of TAp63-regulated miRNAs in these two processes
remained unexplored. Interestingly, several of the miRNAs that were found to be
overexpressed in this analysis have been previously implicated in the pathogenesis
of cuSCC, including miRs-15b, 17, and 27b (72, 150, 152, 239). Conversely, several
miRNAs that were underexpressed, including miRs-30c-2* and 497, were found to
be frequently reduced in cuSCC and found to exhibit tumor suppressive functions
(72, 150). Despite the implication of these miRNAs in cuSCC, the specific identities
of the most significant mRNA targets and their functions remain to be characterized.
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Figure 8: TAp63-deficient tumors exhibit deregulated mRNA and miRNA
expression. (A) Principal component analysis (PCA) plot of global mRNA
expression in murine WT and TAp63-/- skin and cuSCC (3 WT normal skin, 3 TAp63/-

normal skin, 2 WT cuSCC tumors, and 3 TAp63-/- cuSCC tumors). (B and C)

Hierarchical clustering analysis based on differentially expressed mRNAs (B) and
miRNAs (C) in TAp63-/- cuSCC tumors vs. TAp63-/- normal skin samples. Each row
represents a single mRNA or miRNA, while each column represents a sample. The
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Pearson correlation matrix is shown on top. The color scale shown in the map
illustrates the relative expression levels of mRNAs and miRNAs across each
sample. Blue shades correspond to reduced expression and red shades represent
increased expression levels. (D) Comparison of the TAp63-/- cuSCC signature and
human cuSCC identified similar differential expression of the indicated number of
miRNAs and mRNAs. (E) GSEA Analysis of the overlapping targets (purple)
identified in (D).
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Figure 9: mRNA and miRNA profiling of WT and TAp63-/- skin and cuSCC.
Unsupervised hierarchical clustering analysis based on differentially expressed
mRNAs (A) and miRNAs (B) in WT and TAp63-/- skin and cuSCC. Each row
represents a single mRNA or miRNA, while each column represents a sample. The
Pearson correlation matrix is shown on top. The color scale shown in the map
illustrates the relative expression levels of mRNAs and miRNAs across each
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sample. Green shades correspond to reduced expression and red shades represent
increased expression levels.
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Figure 10: Functional pair analysis identifies TAp63-associated miRNA-mRNA
regulatory networks in cuSCC. (A) Underexpressed miRNAs with predicted
mRNAs that are overexpressed in the TAp63-/- cuSCC signature.
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Figure 11: Functional pair analysis identifies TAp63-associated miRNA-mRNA
regulatory networks in cuSCC. Overexpressed miRNAs with predicted mRNAs
that are underexpressed in the TAp63-/- cuSCC signature.
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3.2.4. TAp63-regulated miR-30c-2* and miR-497 suppresses cuSCC through
induction of cell death and cell cycle arrest
We utilized Taqman qRT-PCR to validate the differential expression of the TAp63associated miRNAs in TAp63-/- cuSCC compared to normal skin. Using these
assays, we were able to validate the significantly increased expression of miR-17*
and reduced expression of miR-30c-2* and miR-497 in murine TAp63-/- cuSCC
(Figure 12A-C). We then profiled the expression of these miRNAs in 2 human
cuSCC cell lines (COLO16 and SRB12) and compared it to their expression in
normal human epidermal keratinocytes (NHEKs), which are believed to be the cell of
origin for cuSCC (Figure 12D). As expected, we found that miR-30c-2* was
underexpressed in both cell lines, while miR-497 was significantly reduced in
COLO16 cells. In parallel, we also examined the expression of TAp63 and Dicer in
these cell lines and found that they are both significantly underexpressed when
compared to NHEKs (Figure 12E). Taken together, these results suggest that the
reduced expression of TAp63 and Dicer is associated with reduced expression of
miR-30c-2* and miR-497.
To further probe the interaction between TAp63, miR-30c-2* and miR-497 in
cuSCC, we used short interfering RNA (siRNA) to knockdown TAp63 in NHEKs
(Figure 12F). Knockdown of TAp63 resulted in diminished expression of miR-30c-2*
(Figure 12H) and miR-497 (Figure 12I), supporting a model in which TAp63
positively regulates the expression of these miRNAs. To determine the mechanism
through which TAp63 may regulate these miRNAs, we examined the expression of
the primary transcripts that encode the mature forms of miR-30c-2* and miR-497.
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While pri-miR-30c-2 was significantly reduced (Figure 12J), pri-miR-497 expression
was increased upon knockdown of TAp63 (Figure 12K). These results suggest that
TAp63 may promote miR-30c-2* expression through direct transcriptional activation
of its precursor transcript. Indeed the promoter of the host gene encoding miR-30c2* contains 2 predicted p63 binding sites (data not shown). Chromatin
immunoprecipitation quantitative PCR (ChIP-qPCR) however failed to show p63
binding to either region (data not shown). These results suggest that TAp63 may
regulate miR-30c-2* and miR-497 through an indirect mechanism. In line with
previous observations, downregulation of TAp63 resulted in a significant reduction in
Dicer mRNA expression (Figure 12G). To determine if this loss of Dicer expression
is responsible for the diminished miR-30c-2* and miR-497 expression following the
downregulation of TAp63, we transfected NHEKs with siRNAs targeting Dicer
(Figure 12L). Downregulation of Dicer resulted in significant reductions of miR-30c2* (Figure 12M) and miR-497 (Figure 12N) expression, similar to what is observed
upon TAp63 knockdown. These observations suggest that TAp63 may regulate both
miR-30c-2* and miR-497 through positive regulation of Dicer-mediated miRNA
biogenesis.
To test the putative anti-tumor effects of miR-30c-2* and miR-497 we
transfected chemically modified miRNA mimics into the human cuSCC cell lines
COLO16 and SRB12 and analyzed cell growth. We found that both miR-30c-2* and
miR-497 significantly inhibited proliferation of COLO16 (Figure 13A) and SRB12
(Figure 13B) cells when compared to a scrambled control mimic. To further dissect
the anti-proliferative effects of these miRNAs, we assayed transfected cuSCC cells
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for DNA synthesis, apoptosis, and cell cycle profiling. We found that miR-30c-2* led
to a significant reduction in Edu incorporation, indicating decreased DNA synthesis
(Figure 13D and Figure 13F). We also saw an even more striking induction of
apoptosis in miR-30c-2*-transfected cells, as evidenced by increased annexin V
staining (Figure 13C Figure 13E). Likewise, miR-497-transfected cells showed an
even more significant reduction in DNA synthesis, as evidenced by a nearly 5-fold
reduction in Edu incorporation (Figure 13D and Figure 13F). miR-497-transfected
cell did not however show increased apoptosis (Figure 13C Figure 13E), as had
been previously reported in breast cancer cells (240). Instead, cell cycle profiling
demonstrated that miR-497-transfected cells exhibited a striking increase in the
percentage of cells in G1, which is indicative of G1/S arrest (Figure 13G and Figure
13AH), and is in accordance with previous studies of miR-497 function in other
cancer cell types (240-242). Alternatively, miR-30c-2*-transfected cells were found
to have a slight, non-significant increase in the percentage of cells in G2 (Figure 13G
and Figure 13H). Taken together these results suggest that miR-30c-2* and miR-497
suppress cuSCC cell growth through the induction of cell death and cell cycle arrest,
respectively.
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Figure 12: TAp63 promotes miR-30c-2* and miR-497 expression through Dicer.
(A-C) Taqman qRTPCR of miR-17* (A), miR-30c-2* (B) and miR-497 (C) in TAp63-/skin and cuSCC samples. (D) SYBR green qRT-PCR of TAp63 and DICER in
human cuSCC cell lines SRB12 and COLO16. (E) Taqman qRTPCR of miR-30c-2*
and miR-497 in human cuSCC cell lines SRB12 and COLO16. (F-G) SYBR green
qRTPCR of TAp63 (F) and Dicer (G) in NHEKs following transfection with the
indicated siRNAs. (H-K) Taqman qRTPCR of miR-30c-2* (H), miR-497-5p (I), primiR-30c-2 (J), and pri-miR-497 (K) in NHEKs following transfection with the
indicated siRNAs. (L) SYBR green qRTPCR of Dicer in NHEKs following transfection

89

with the indicated siRNAs. (M and N) Taqman qRTPCR of miR-30c-2-3p (M) and
miR-497-5p (N) in NHEKs following transfection with the indicated siRNAs. Data
shown are mean ± SD, n=3. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 twotailed t test.
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Figure 13: TAp63-regulated miR-30c-2* and miR-497-5p suppresses cuSCC
through induction of cell death and cell cycle arrest. (A and B) Representative
growth curve of nucRed-mCherry-labeled COLO16 (A) and SRB12 (B) cells
transfected with the indicated miRNA mimics. (C and E) Immunofluorescence (C)
and quantification (E) for Annexin V-488 (green)-positive COLO16 cells transfected
with the indicated miRNA mimics. (D and F) Immunofluorescence (D) images and
quantification (F) for Edu (green) incorporation in COLO16 cells transfected with the
indicated miRNA mimics following a 3 hour Edu pulse. NucRed® dead 647 (red) was
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used as a counterstain (G and H) Cell cycle profiles (G) and quantification (H) of
COLO16 cells 48 hours after transfection with the indicated miRNA mimic as
measured by FACS analysis. M phase was measured as the percentage of cells
staining positive for Histone H3-pS28-AF647. Data shown are mean ± SD, n=3,
unless noted otherwise. * p<0.05, ** p<0.01, ***p<0.001, two-tailed t test.
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3.2.5. miR-30c-2* and miR-497 suppress cuSCC growth in vivo
To extend these observations to an in vivo setting, we generated COLO16 cells that
stably express an RFP-luciferase reporter. These cells were then transfected with
mimics of miR-30c-2*, miR-497, or negative control, and subsequently xenografted
into athymic nu/nu mice (Figure 14A). In accordance with our in vitro observations,
transfection of miR-30c-2* or miR-497 almost completely abolished the tumor growth
of COLO16 cells compared to controls (Figure 14B-E). Collectively, these
observations suggest that miR-30c-2* and miR-497 suppress cuSCC tumor growth
in vivo.
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Figure 14: miR-30c-2* and miR-497 suppress cuSCC growth in vivo. (A)
COLO16 cells stably expressing RFP and luciferase were transfected with the
indicated miRNA mimics and subcutaneously injected into both flanks of athymic
nu/nu mice. (B) Representative images of mice injected with COLO16 cells
transfected with scrambled, miR-30c-2-3p, and miR-497-5p miRNA mimics on Day
19 prior to tumor harvest. (C-D) Tumor volume was assessed was assessed using
caliper measurements (C) and luminescence imaging (D). (E) Quantification of
extracted tumor volumes. Data shown are mean ± SEM, n=10.
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3.2.6. Intravenous injection of miRNA mimics fails to inhibit growth of cuSCC
xenografts.
Next, we assessed whether intravenous delivery of miR-30c-2* and miR-497 miRNA
mimics showed anti-tumor effects in the COLO16 cuSCC xenograft model. Tumorbearing athymic nu/nu mice were treated with intravenous injections of either miR30c-2*, miR-497, or scrambled mimics complexed with in vivo-jetPEI® reagent, 3
times per week. Compared to the scrambled control, neither miR-30c-2*, nor miR497 had a significant effect on tumor growth (Figure 15A). To determine if this lack of
a tumor response was due to inadequate intratumoral delivery of the miRNA mimics,
I performed Taqman qRT-PCR to assay the expression of either miRNA in the
corresponding tumors and organs of the mimic-injected mice. Surprisingly, there was
only a modest increase in the amount of miR-30c-2* present in the tumors of the
miR-30c-2* mice relative to scrambled mimic injected mice (Figure 15B). In contrast,
miR-497 injected mice showed no significant increase in miR-497 compared to
control (Figure 15C). Notably, the amount of miR-30c-2* and miR-497 were
increased dramatically in the livers of miR-30c-2* and miR-497-injected mice,
respectively (Figure 15B and Figure 15C). Attempts to increase the dosage of
miRNA mimic resulted in significant toxicity and caused lethality in mice, presumably
due to the preferential accumulation in the liver versus tumor (data not shown).
Taken together, these results indicate that the in vivo-jetPEI® reagent failed to
adequately deliver the miRNA mimics to the xenograft tumors, and precluded the
possibility to investigate their therapeutic potential.
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Figure 15: Intravenous injection of miRNA mimics fails to inhibit growth of
cuSCC xenografts. (A) COLO16 cells stably expressing RFP were subcutaneously
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3.2.7. Cross-platform analysis identifies multiple direct mRNA targets for miR30c-2* and miR-497
The ultimate consequence of miRNA function is the translational inhibition of the
mRNAs that it targets. Therefore, to study the regulatory functions of miR-30c-2* and
miR-497, we employed a quantitative mass spectrometry-based approach to
measure global protein expression following overexpression of either miRNA (Figure
17A). COLO16 cells were transfected with miR-30c-2*, miR-497 or scrambled
control mimics and collected 48 hours later. Cell lysates were alkylated and
subjected to tryptic digestion, followed by Tandem mass tag (TMT) labeling.
Peptides were then identified via LC-MS/MS and proteins that were quantified by at
least 2 unique peptides were selected for further analysis. Differential protein
expression was determined as the relative protein ratio of the differentially labeled
peptide fractions in each mimic transfected sample compared to the scrambled
mimic control.
A total of 1751 proteins were differentially expressed based on an absolute
fold change greater than 1.5 in the miR-30c-2*-transfected sample relative to the
scrambled mimic-transfected sample (Figure 17B). Among these proteins, 361 were
underexpressed, while 1390 proteins were increased relative to control-transfected
cells. Alternatively, 587 proteins were differentially expressed in the miR-497transfected sample relative to control with 275 proteins being underexpressed, and
312 proteins were overexpressed (Figure 17C). Notably, we did not see reduced
expression for any of the previously published targets of miR-30c-2* as being
significantly reduced in the miR-30c-2* transfected cells. Likewise, we only found
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two previously published targets of miR-497 (ANLN and CDK6) as being significantly
underexpressed in the miR-497 comparison (243, 244). The discordance between
our proteomics data and the previously identifed targets of miR-30c-2* and miR-497
suggest that the targets of a given miRNA may differ, according to the specific
cellular and physiological context. As a result, the data generated in this study may
reveal previously unidentified targets of miR-30c-2* and miR-497 that are
functionally relevant to the pathogenesis of cuSCC.
Ingenuity pathway analysis (IPA) was performed to identify the significantly
enriched canonical pathways among the underexpressed proteins in both
comparisons. Interestingly, the proteins that were underexpressed in the miR-30c2*-transfected cells were significantly enriched for pathways related to ErbB
signaling, including Agrin Interactions at Neuromuscular Junction, Neuregulin
Signaling, and ErbB2-ErbB3 Signaling (Figure 16A). Alternatively, the top pathway
enriched in the underexpressed proteins in the miR-497 comparison was Mitotic
Roles of Polo-like kinase (Figure 16B). Each of these pathways exhibited a negative
z-score, indicating that the activity of the pathways are predicted to be reduced in
the miRNA mimic transfected cells, which is corroborated by our phenotypic assays.
Taken together these results indicate that the global proteomics changes identified
by this method accurately reflect the phenotypic changes observed following the
overexpression of the corresponding miRNA.
Given that miRNAs function to inhibit protein translation, it was surprising to
see such a large percentage of proteins exhibiting an increase in expression
following miR-30c-2* overexpression. This, however may be due to the increased
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fraction of miR-30c-2* transfected cells in the G2 phase of the cell cycle, which is
typically characterized by increased protein synthesis which prepares the cell for
mitosis and cell division (Figure 13H). To test this hypothesis, we performed
Ingenuity Pathway Analysis on the overexpressed proteins in the miR-30c-2* vs.
scrambled control comparison (fold change > 1.5) (Figure 16C). This analysis
showed enrichment for pathways related to protein synthesis, including EIF2
signaling, as well as enrichment for pathways related to cell growth and division,
including Actin Cytoskeleton, Integrin Signaling, and RhoA signaling. These results
suggest that miR-30c-2* expression induces a G2/M arrest.
To determine if the measured protein expression changes reflect direct
regulatory effects of miR-30c-2* and miR-497, we profiled the corresponding mRNA
for each of the differentially expressed proteins in each comparison for the presence
of miRNA response elements (MREs) for the respective miRNA utilizing the miRwalk
2.0 software (245). This software allowed us to leverage 4 different miRNA target
prediction algorithms, including miRwalk, miRanda (125), Targetscan (246), and
RNA22 (247). From this analysis, we found that 243 of the 361 (67.3%)
underexpressed proteins harbored a predicted MRE for miR-30c-2*. Unexpectedly,
we found that 875 of the 1390 (62.9%) overexpressed proteins harbored a predicted
MRE for miR-30c-2*, indicating that there was not a significant enrichment for the
presence of predicted MREs in the underexpressed fraction, as was expected.
Likewise,

among

the

differentially

expressed

proteins

following

miR-497

overexpression, we found 160 of the 275 underexpressed proteins (58.18%) and
171 of the 312 overexpressed proteins (54.81%) to have predicted MREs for miR-
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497. Interestingly, these analyses failed to show a significant enrichment for
predicted MREs among the underexpressed proteins.
To prioritize targets for further validation, we compared the list of
underexpressed proteins (fold change < 0.67) in the miR-30c-2* (Figure 17D) and
miR-497 (Figure 17E) proteomics signatures against the mRNAs that were
conversely overexpressed (fold change > 1.5, p < 0.05) in both the mouse TAp63-/cuSCC and human cuSCC RNA-seq signatures. We then examined both lists of
mRNAs for the presence of at least one MRE to focus our studies on likely targets of
either miRNA. From this analysis we found 5 putative targets of miR-30c-2* (FAT2,
ITGA6, KIF18B, ORC1, and PKMYT1) and 4 predicted targets of miR-497 (AURKA,
CDK6, KIF18B, and PKMYT1) that are frequently overexpressed in both mouse
TAp63-/- and human cuSCC. Interestingly, both miRNAs are predicted to target
KIF18B and PKMYT1. We validated the LC-MS/MS observations for all 7 of the
putative targets by Western blotting (Figure 17F-H). Interestingly, only AURKA and
CDK6 appeared to be significantly reduced at the RNA level following
overexpression of miR-497, whereas none of the miR-30c-2* targets were affected
(Figure 17I and Figure 17J). These results confirm that all 7 targets are significantly
downregulated following overexpression of the corresponding miR and suggest that
they may be directly inhibited via miRNA-mRNA mediated targeting.
To determine if the putative targets of either miRNA are repressed via RISCmediated miRNA-mRNA interaction we transfected COLO16 cells with miRNA
mimics biotinylated at the 3’-end of the mature strand (bi-miR-30c-2*, bi-miR-497, or
bi-scrambled). We then performed streptavidin pull-downs and performed qRT-PCR
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for each of the putative targets of miR-30c-2* and miR-497, as well as GAPDH for
normalization purposes (248). Relative mRNA abundance in the streptavidin pulldowns and inputs in the bi-miR-30c-2*- and bi-miR497-transfected cells were
separately normalized to their levels in cells transfected with a biotinylated
scrambled mimic (bi-scrambled). The putative miR-30c-2* targets FAT2, ORC1,
KIF18B, and PKMYT1 were significantly enriched in the bi-miR-30c-2* pull-down
(Figure 17K). While not significant, enrichment for ITGA6 trended towards
significance. Similarly, all 4 putative targets of miR-497 (AURKA, CDK6, KIF18B,
and PKMYT1) were enriched in the bi-miR-497 pull-down (Figure 17L). Taken
together, these results suggest that FAT2, ITGA6, ORC1, KIF18B and PKMYT1
appear to be novel direct targets of miR-30c-2*, while AURKA, CDK6, KIF18B, and
PKMYT1 seem to be bona fide targets of miR-497.
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Figure 16: Identification of miRNA targets through the use of TMT-LC-MS/MS.
(A and B) Ingenuity Pathway Analysis (IPA) of underexpressed proteins (fold change
< 0.67) in cells transfected with miR-30c-2-3p (A) and miR-497-5p (B) compared to
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scrambled control. The canonical pathways shown exhibited a -log(p-value) > 2, and
an absolute z-score > 1.5. A positive (orange bars) or negative (blue bars) z-score
indicates that a given pathway is predicted to be increased or reduced following
overexpression of the corresponding miRNA mimic. (C) Ingenuity Pathway Analysis
of the overexpressed proteins (fold change > 1.5) in cells transfected with miR-30c2-3p compared to scrambled control. The canonical pathways shown exhibited a log(p-value) > 5, and an absolute z-score > 4.
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Figure 17: Cross-platform analysis identifies direct mRNA targets for miR-30c2* and miR-497. (A) Schematic representation of experimental design. COLO16
cells transfected with the indicated miRNA mimic were collected, denatured, and
subjected to tryptic digest prior to labeling of each sample with the indicated tandem
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mass tag (TMT). Labeled peptides were then combined, fractionated and subjected
to LC-MS/MS analysis to identify differentially expressed proteins. (B and C)
Differential protein expression changes in cells transfected with miR-30c-2-3p (B) or
miR-497-5p (C) mimics compared to scrambled control. (D and E) Comparison of
significantly underexpressed proteins following transfection with miR-30c-2* (D) and
miR-497 (E) with the overexpressed mRNAs in murine TAp63-/- cuSCC and human
cuSCC by RNAseq. Overlapping targets were examined for the presence of MREs
for miR-30c-2* and miR-497. Note that KIF18B and PKMYT1 were found to be
predicted targets of both miR-30c-2* and miR-497-5p and were underexpressed in
both proteomics experiments. (F-H) Western blot analysis for the indicated proteins
following transfection with mimics of miR-30c-2* (F), miR-497 (I), and both miRs (J).
(I and J) Taqman qRTPCR of the putative targets of miR-30c-2* (I) and miR-497-5p
(J). COLO16 cells following transfection with the indicated mimics. (K and L)
COLO16 cells were transfected with the indicated biotinylated miRNA mimics (bimiR) and collected 24 hrs after transfection. Fold enrichment for the indicated
targets in the streptavidin pull-down of bi-miR-30c-2-3p (n=5) (K) and bi-miR-497-5p
(n=3) (L) was calculated using qRT-PCR. Data shown represent the mean ± SD of at
least 3 independent experiments, unless noted otherwise. * p<0.05, ** p<0.01, ***
p<0.001, two-tailed Student’s t test.
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3.2.8. miR-30c-2* and miR-497 targets promote tumor cell proliferation and
survival
To determine if the verified targets of miR-30c-2* and miR-497 are relevant to
human tumors, we profiled their expression by Western blot in 5 human cuSCC cell
lines (COLO16, SRB12, SRB1, IC1, and RDEB2) and compared it to their
expression in NHEKs (Figure 18A). From these experiments, we found that each of
these targets are overexpressed in the majority of the cuSCC cell lines profiled, with
the exception of FAT2 and PKMYT1, which showed variable expression across the
different cuSCC cell lines.
Given that overexpression of miR-30c-2* and miR-497 can impair cell
proliferation and induce cell death, we asked whether depletion of these putative
targets could produce the same biological effects. To do so, we utilized siRNAmediated gene silencing to knock down each individual target in COLO16 and
SRB12 cells (Figure 18B). Knockdown of all 7 targets in SRB12 cells caused
decreased growth of SRB12 cells (Figure 19A). Interestingly, knockdown of FAT2 and
CDK6 caused an increase in cell proliferation in COLO16 cells, whereas knockdown
of KIF18B, PKMYT1, ORC1, and AURKA resulted in significant reductions in
COLO16 growth (Figure 18C). These results suggest that KIF18B, ORC1, PKMYT1,
and AURKA may be oncogenic drivers of cuSCC.
To determine if inhibition of these targets may induce apoptosis, we
performed Annexin V assays in COLO16 and SRB12 cells transfected with siRNAs
targeting each of the 6 targets. Knockdown of FAT2, ORC1, KIF18B, PKMYT1, and
AURKA led to significant increases in cell death in COLO16 cells, (Figure 18D and
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Figure 18E). In SRB12 cells, however, only knockdown of FAT2 and AURKA caused
significant increases in apoptosis (Figure 19B and Figure 19C).
We next asked whether inhibition of these targets can phenocopy the effects
miR-30c-2* or miR-497 overexpression had on the cell cycle of COLO16 cells. Cell
cycle profiling showed that ORC1 knockdown resulted in an apparent G2/M arrest,
resembling the effects miR-30c-2* overexpression (Figure 18F). Knockdown of the
miR-497 targets did not lead to a G1/S arrest, however, suggesting that miR-497
mediates this effect through the inhibition another target(s), or a combination thereof.
Interestingly, AURKA inhibition resulted in significant reductions in the percentage of
cells in G1 and S phase, and increases in the percentage of cells in G2 and M
phase. Interestingly, the percentage of cells that stained positive for histone H3 S28
phosphorylation was significantly elevated in AURKA knockdown cells, indicating
increased mitosis. This phenotype, along with increased apoptosis, is suggestive of
mitotic cell death, a process in which aberrant mitotic activity results in cell death or
irreversible cellular senescence (249). These results suggest that these targets may
be viable therapeutic targets for the treatment of cuSCC.
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Figure 18: Inhibition of mIR-30c-2* and miR-497-5p targets affects cuSCC cell
proliferation and survival. (A) Representative results of Western blotting of the
validated miR-30c-2* and miR-497 targets in NHEKs and the cuSCC cell lines
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COLO16, SRB12, SRB1, IC1, and RDEB2. (B) Representative Western blotting of
the indicated targets following siRNA-mediated knockdown. (C-E) COLO16 cells
stably expressing nuclear mCherry transfected with the indicated siRNAs, incubated
with Annexin V-488, and scanned every 4 hours using the Incucyte® high-content
live-cell imaging platform. (C) Growth curve of COLO16 cells transfected with the
indicated siRNAs. (D and E) Immunofluorescence (D) and quantification (E) for
annexin V-488 (green)-positive cells transfected with the indicated siRNAs. (F) Cell
cycle profiles of COLO16 cells were assessed by FACS 48 hours after siRNA
transfection. Data shown are mean ± SD, of at least 3 independent experiments. *
p<0.05, ** p<0.01, ***p<0.001, two-tailed Student’s t test.
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Figure 19: Inhibition of miR-30c-2-3p and miR-497-5p targets affects SRB12
cell proliferation and survival. (A-C) SRB12 cells stably expressing nuclear
mCherry were transfected with the indicated siRNAs, incubated with Annexin V-488,
and scanned every 4 hours using the Incucyte® high-content live-cell imaging
platform. (A) Growth curve of SRB12 cells transfected with the indicated siRNAs.
Immunofluorescence (C) and quantification (B) for annexin V-488 (green)-positive
cells transfected with the indicated siRNAs. Data shown are mean ± SD, of at least 3
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independent experiments. * p<0.05, ** p<0.01, ***p<0.001, two-tailed Student’s t
test.
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3.2.9. AURKA is a viable therapeutic target in cuSCC
To investigate if TAp63 and these miRNAs interact in human patient cuSCC, we
performed correlation analyses of miR-30c-2* and miR-497 with the mRNA
expression of the 7 validated targets described above. While miR-30c-2* did not
show significant correlation with any the targets identified in this study (data not
shown), we found significant negative correlation between miR-497 and AURKA
(Figure 20C) (r = -0.79, p-value=2.44 104) and PKMYT1 (Figure 20B) (r = -0.58, pvalue-0.019) mRNA expression. The expression of miR-497 and KIF18B was
negatively correlated, however this trend was not statistically significant (r = -0.46, pvalue=0.07) (Figure 20A). These results suggest that miR-497 may regulate the
expression of AURKA and PKMYT1 in human cuSCC.
We next asked whether the expression levels of miR-30c-2*, miR-497, or the
targets validated in this study could predict patient survival. To do so, we leveraged
the publically available data from the Cancer Genome Atlas (TCGA). We decided to
focus our analyses on HNSCC, which has been shown to be the tumor type that is
most closely related to cuSCC (72). From this analysis, we found that high
expression of miR-497 correlated with improved survival outcomes in patients with
HNSCC (Figure 20D). Conversely, HNSCC patients with high expression of AURKA
showed significantly reduced survival (Figure 20E). Taken together these
observations suggest that miR-497-mediated regulation of AURKA is functionally
and clinically important in cuSCC and HNSCC.
To pursue the potential therapeutic significance of these findings, we treated
COLO16 cells with the AURKA-selective kinase inhibitor alisertib. Using the
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CellTiter-Glo® assay to quantify cell viability, we found that alisertib was particularly
potent in its ability to reduce the viability of COLO16 cells (IC50 = 0.01225µM)
(Figure 20F). We then asked whether alisertib could reduce cell proliferation and
induce cell death in COLO16 cells to the same extent as siRNA-mediated
knockdown of AURKA. High content live cell imaging demonstrated that cell
proliferation was almost completely inhibited by alisertib treatment (0.01225µM)
(Figure 20H). Additionally, alisertib treatment (0.01225µM, 72 hours) resulted in
significant apoptosis to the same extent as siRNA-mediated knockdown of AURKA
(Figure 20H and Figure 20I). Overall, these results highlight the therapeutic potential
of alisertib in the treatment of cuSCC.
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Figure 20: AURKA is a viable therapeutic target in cuSCC. (A-C) Correlation
analysis of miR-497 and KIF18B (A), PKMYT1 (B), and AURKA (C) in human
cuSCC tumors. Pearson’s correlation coefficient (r) values and p values are listed.
(D and E) Kaplan-Meier survival curves from HNSCC patients with high vs. low
expression of miR-497 (D) and AURKA (E). (F) Effect of alisertib treatment on
COLO16 cells. (G-I) COLO16 cells stably expressing nuclear mCherry treated with
DMSO vs. alisertib (0.01225uM), incubated with Annexin V-488, and scanned every
6 hours using the Incucyte® high-content live-cell imaging platform. (G) Growth
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3.2.10. Discussion
Recent genomic and molecular pan-cancer profiling studies of human patient tumors
indicate that TP63 gene plays a central role in the pathogenesis of almost every type
of SCC, including the skin, head and neck, lung, esophagus, bladder, and cervix (68,
70-74, 250). In fact, amplification of chromosome 3q, which harbors the TP63 gene,
is the most common copy number alteration across all human SCC (68). Importantly,
however, TP63 is expressed as two different groups of isoforms due to the presence
of two alternative promoter regions. TAp63 isoforms contain an N-terminal acidic
transactivating domain (TA), which is highly homologous to the TA domain present
in the p53 gene. ΔNp63 isoforms on the other hand lack this domain and frequently
exert inhibitory function on TAp63 and p53 (21, 24). The use of isoform-specific
reagents and next generation sequencing led to the discovery that ΔNp63 isoforms
are frequently overexpressed in human tumors, including SCC, whereas TAp63
isoforms are typically not expressed or are expressed at very low levels (63). The
differential expression of the N-terminal isoforms may be due to the differential
methylation status of the alternative transcriptional start sites for TA and ΔN isoforms
(68, 251). Together, these studies support a paradigm where TAp63 functions as a
tumor suppressor, while ΔNp63 predominantly functions as an oncogene.
In this study, I found that TAp63 functions as a tumor suppressor in UVRinduced cuSCC. Using a commonly employed mouse model for this disease I found
that mice lacking TAp63 are more susceptible to UVR-induced cuSCC. We
previously demonstrated that TAp63 promotes miRNA expression through
transcriptional regulation of Dicer. Therefore, we asked whether or not TAp63-
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mediated miRNA expression might account for the increased tumor susceptibility of
TAp63-/- mice. To answer this question we performed RNA-seq from wild type and
TAp63-/- skin and cuSCC lesions. This study revealed significant perturbations in
global miRNA and mRNA expression in TAp63-deficient tumors. A human to mouse
cross-species analysis of the TAp63-/- cuSCC signature with similarly sequenced
human cuSCC lesions identified miR-30c-2* and miR-497 as significantly
underexpressed in both human and mouse tumors. Transfection of cuSCC cell lines
with miR-497 mimics caused a dramatic decrease in proliferation.

Conversely,

introduction of miR-30c-2* mimics in cuSCC cell lines induced significant apoptosis.
Proteomic profiling of cuSCC cell lines transfected with miR-30c-2* and miR-497
mimics and subsequent validation experiments led to the discovery of novel direct
targets of miR-30c-2* and miR-497. A cross-platform comparison of the RNA-seq
and

proteomics

signatures

identified

7

downregulated

proteins,

whose

corresponding mRNAs were also overexpressed in both mouse and human cuSCC.
The most relevant of these proteins exhibited pro-oncogenic functions, including
roles in cell cycle and mitotic progression.
Inhibition of the miRNA targets including AURKA, KIF18B, PKMYT1, and
ORC1 in cuSCC cell lines suppressed tumor cell proliferation and induced cell
death. Interestingly, the expression of miR-497 and AURKA showed a significant
negative correlation in human cuSCC patient samples. We also found that high
expression of miR-497 correlated with improved survival outcomes in patients with
HNSCC. Conversely, HNSCC patients with high expression of AURKA showed
significantly reduced survival. Taken together these observations suggest that miR-
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497-mediated regulation of AURKA is functionally and clinically important in cuSCC
and HNSCC.
Notably, AURKA inhibition has not been investigated as a potential treatment
option for human cuSCC. My observations suggested that AURKA might be an
effective therapeutic target in SCC. I utilized siRNA-mediated knockdown, as well as
the FDA-approved AURKA inhibitor alisertib to investigate the effect of AURKA
inhibition on cuSCC cell growth and survival. Through these experiments, I found
that inhibition of AURKA potently suppressed cuSCC cell growth and induced cell
death. Collectively, these observations suggest that AURKA may be an effective
targeted therapy in cuSCC.
This study establishes TAp63 as an essential regulator of miRNA expression
during skin carcinogenesis and reveals a previously undescribed functional network
of miRNAs and targeted mRNAs. These include viable, yet previously unexplored
targets for the treatment of human cuSCC.
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Chapter 4: TAp73 suppresses lung adenocarcinoma development and
progression
4.1. Introduction
The p53 family of transcription factors has been implicated in multiple tumor types
including lung adenocarcinoma (LUAC). While p53 is mutated or deleted in a very
large percentage of LUAC (47%), p63 and p73 are less frequently mutated (6% and
3%, respectively) (68, 71). The role of p73 in lung cancer however has not been fully
investigated. While p73 is rarely mutated in human cancers, studies in geneticallyengineered mouse models (GEMMs) have found that the depletion of p73 promotes
tumor development (184, 185). Notably, 60% of p73-/- mice develop LUAC (184).
Importantly, p73 is expressed as complex isoforms due to the presence of two
alternative promoters (Figure 1). This results in two classes of N-terminal isoforms,
which are typically referred to as TAp73 and ΔNp73. TAp73 isoforms contain an Nterminal transactivation domain (TA) that is highly homologous to the TA domain of
p53. This domain is important for the transactivation of multiple transcriptional target
genes, including canonical p53 targets (1). Moreover, TAp73-/- mice are tumor prone,
further supporting the hypothesis that TAp73 is a bona fide tumor suppressor (185).
Importantly, 32% of these mice develop LUAC, further suggesting that TAp73
functions as a tumor suppressor in the lung.
To investigate the contribution of TAp73 to LUAC development and
progression, we generated a novel TAp73 conditional knockout mouse model and
combined it with the autochthonous oncogenic KRAS lung adenocarcinoma mouse
model (Figure 5) (214, 252). This model, as opposed to orthotopic models in
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immune-deficient mice, is useful for interrogating the interactions between tumor
cells, the immune system, and the tumor microenvironment.
Here we investigated the role of TAp73 during oncogenic Kras-driven lung
tumorigenesis using the Cre-inducible KrasLSLG12D/+ knock-in mouse model (206,
214) and human LUAC cell lines. We found that the genetic deletion of TAp73
isoforms promoted the development of lung adenomas and LUAC. In addition, we
also found that loss of TAp73 resulted in higher grade tumors and increased tumor
vascularization. Interestingly, we found that TAp73-deleted tumors exhibited reduced
CD8+ and CD4+ T cell infiltration. The results from this study show that TAp73 is a
potent tumor suppressor in the lung, through both cell-autonomous and non-cell
autonomous mechanisms.

4.2. Results
4.2.1 Generating the TAp73 conditional knockout reporter (TAp73fltd) mouse
We generated a TAp73 conditional knockout reporter mouse (TAp73fltd) using the
cre-loxP system (Figure 21A) to enable tissue- and temporal-specific deletion of the
TAp73 isoforms without affecting expression of ΔNp73 isoforms. LoxP sites were
cloned into the endogenous p73 gene flanking exons 2 and 3, which contains the
translational start site for the TAp73 isoforms. The tdTomato gene was inserted
upstream of the 5’ loxP site in the anti-sense direction, along with a synthetic CAG
promoter downstream of the 3’ loxP site. Correctly targeted mouse embryonic stem
cells (mESCs) were injected into donor blastocysts, which were subsequently
implanted into pseudopregnant females. Resulting chimeric mice were intercrossed
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with albino C57BL/6J to facilitate the identification of efficient germline transmission,
which was subsequently confirmed by genotyping PCR and Southern blot analysis
(Figure 21B-D).
To understand the role of TAp73 in development, we generated TAp73
knockout mice (TAp73∆td/∆td) by intercrossing TAp73fltd/fltd mice with transgenic mice
expressing a germline-specific Cre (Zp3-Cre) (216). Cre-mediated recombination
resulted in the deletion of exons 2 and 3, and strong tdTomato expression (Figure
21B-E). Quantitative RT-PCR on mouse embryonic fibroblasts (MEFs) isolated from
WT and TAp73∆td/∆td embryos confirmed the depletion of TAp73 mRNA (Figure 21E
and Figure 21F) without affecting ΔNp73 expression (data not shown). Taken
together, these results indicate that our targeting strategy efficiently, and correctly
ablates TAp73 expression without affecting the expression of ΔNp73 isoforms.
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Figure 21: Generating the TAp73 conditional knockout reporter (TAp73fltd)
mouse. (A) The TAp73 targeting vector was generated by inserting loxP sites
(triangles) flanking exon 2 and a neomycin resistance (neo) cassette flanked by frt
sites (purple circles) in intron 3. Primers used for genotyping by PCR of wild-type
(blue) and TAp73 conditonal knockout reporter (fltd) (pink), and knockout (Δtd)
(green) alleles are shown. (B and C) Southern blot analysis of genomic DNA from
WT, TAp73fltd/fltd, and TAp73Δtd/Δtd mice. 5’ external probe (B) is shown as a red line
at the 3’ end of exon 1 in (A). The tdTomato internal probe (C) is depicted as a pink
line under the tdTomato coding sequence in (A). (D) Genotyping PCR of gDNA from
TAp73fltd/Δtd, and TAp73fltd/+ mice. (E) Representative merged immunofluorescent
micrographs of WT and TAp73Δtd/Δtd mouse embryonic fibroblasts (MEFs). (F)
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Taqman qRT-PCR for TAp73 mRNA from WT and TAp73Δtd/Δtd MEFs (n=3 embryos
per genotype, ** p<0.01).
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4.2.2. Loss of TA73 expression promotes lung adenocarcinoma initiation and
progression
To study the role of TAp73 deletion in lung tumorigenesis, we intercrossed
TAp73fltd/fltd mice with the KrasLSLG12D/+ mouse model (206, 214). This model allowed
us to interrogate the effects of TAp73 deletion on oncogenic Kras-driven LUAC. This
model faithfully recapitulates many of the histological features of human LUAC. To
permanently label cells that undergo Cre-mediated recombination, we utilized a
conditional fluorescent reporter allele (RosamT/mG) (213), in which a floxed tdTomato
allele is placed upstream of a stop codon and GFP. This allows for the conditional
activation of GFP expression upon Cre-mediated recombination. Adenovirus
expressing Cre recombinase (Ad-Cre) or empty vector (Ad-Empty) was delivered to
TAp73fltd/fltd;

RosamT/mG

(T),

KrasLSLG12D/+;

RosamT/mG

(K),

and

TAp73fltd/fltd;

KrasLSLG12D/+; RosamT/mG (TK) mice via intratracheal administration. The mouse
models were infected with Ad-Cre at 8-10 weeks of age, and euthanized 30 weeks
later. As expected, all of the TK and K mice developed primary lung tumors following
infection with Ad-Cre (Figure 22A), whereas none of the mice infected with Ad-empty
developed any tumors. At this time point, none of the infected T mice showed
evidence of lung tumorigenesis (data not shown). These results might be expected,
considering the long latency of tumor development in TAp73-/- mice developed by
the Mak laboratory (185).
To investigate the effects of TAp73 loss, we evaluated the lung tumor
phenotypes of K and TK mice. To do so, we imaged H&E stainings taken from the
lungs of infected mice and subjected them to image analysis using machine learning
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software (Visiopharm v 7.2) (Figure 22B). From this analysis we found that the
deletion of TAp73 in the context of oncogenic Kras led to a significant increase in the
total number of lung tumors (Figure 22D), as well as the percentage of lung tumor
area (Figure 22E). These results suggest that TAp73 may suppress lung tumor
initiation.
To determine the effects of TAp73 on tumor progression we set out to
quantify the distribution of tumors based on histopathological grade, using a widely
used grading system for NSCLC mouse models (208). In this system, grade 1 and
grade 2 tumors resemble human pre-malignant lung adenomas, while grade 3 and
grade 4 tumors are comparable to fully-malignant human LUAC. Interestingly,
manual grading of the lung lesions that were identified in our cohort and subsequent
quantification showed that there was a significant increase in the proportion of grade
3 tumors in the infected TK mice, compared to K mice (Figure 22F and Figure 22G).
Taken together, these results suggest that TAp73 may inhibit both lung tumor
initiation and malignant progression.
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Figure 22: Loss of TA73 expression promotes lung adenocarcinoma initiation
and progression. (A) Representative bright field (BF) and GFP imaging of
KrasLSLG12D/+; RosamT/mG (“K”, n=12) and TAp73fltd/fltd; KrasLSLG12D/+; RosamT/mG (“TK”,
n=13) mouse lungs 30 weeks after intratracheal adenoviral-Cre administration. Scale
bar = 5000µm. (B) Representative H&E stainings and tissue segmentation (orange)
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of K and TK mouse lung sections following intratracheal infection with Ad5-CMV-Cre
virus. (C) Taqman qRT-PCR for TAp73 and ΔNp73 mRNA from K and TK LUAC
tumors (n=3 tumors per genotype, ** p<0.01). (D) Average number of tumors per
mouse in K (blue) and TK (red) mice 30 weeks after intratracheal adenoviral Cre
administration. Each dot corresponds to the average number of lung lesions per
section for a single mouse. (E) Average percentage of tumor area in K mice (blue
columns) and TK mice (red columns). Columns correspond to percentage of lung
area occupied by tumors. (F and G) Number (F) and percentage (G) of lung tumor
grades in K (blue columns, n=5) and TK (red columns, n=5) mice. Data shown
represent the mean ± SD; * p<0.05, ** p<0.005, ***p<0.0001.
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4.2.3. TAp73-deficient tumors exhibit reduced immune cell infiltration
Previous studies have implicated p73 isoforms, including TAp73, in normal immune
responses (10, 183, 253). Therefore, we profiled K and TK lung tumors for various
immune markers using immunohistochemical (IHC) staining (Figure 23A). In line
with previous observations (254), we found that TK lung adenomas and lung
adenocarcinomas exhibited a greater degree of CD31 staining, which is a marker for
endothelial cells, indicating increased tumor angiogenesis (Figure 23B). These
results support the hypothesis that TAp73 suppresses tumor angiogenesis (253,
254).
Previous studies have implicated p73 isoforms, including TAp73, in immune
responses. We also assessed the degree of T cell infiltration in T and TK tumors
(Figure 23A-E). Interestingly, there was a significant reduction in the average
number of tumor-infiltrating lymphocytes in TK tumors relative to K tumors (Figure
23A and Figure 23C). Specifically, we found reduced infiltration of both CD4+ helper
T cells and CD8+ cytotoxic T cells in TK tumors when compared to K tumors (Figure
23D and Figure 23E). PD-L1 and FOXP3 however showed no significant changes
between the 2 genotypes (data not shown). Taken together, these results suggest
that the loss of TAp73 hinders an adaptive anti-tumor response, which occurs in
single mutant K mice.
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Figure 23: TAp73-deficient tumors exhibit reduced immune cell infiltration. (A)
Representative immunohistochemistry on mouse lung sections with the indicated
histopathological markers. Scale bars = 200µm. (B) Quantification of the percentage
of intratumoral CD31 staining (n=4 and 6 mice). (C-E) Quantification of CD3+ (n=12
and 14 mice) (C), CD8+ (n=12 and 13 mice) (D), and CD4+ (n=10 and 14 mice) (E)
cell densities in lung tumors. Data shown represent the mean ± SD; * p<0.05, **
p<0.005, ***p<0.0001; two-tailed Student’s t test.
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4.2.4. Deletion of TAp73 using CRISPR/Cas9 leads to deregulated cytokine
secretion
To establish human cell line model system for mechanistic studies, we utilized a
lentiviral-based Crispr-Cas9 strategy to delete TAp73 isoforms in A549 cells. A549
cells-stably expressing Cas9-eGFP were transduced with lentiviruses expressing
mCherry and sgRNAs targeting 3 different regions of the TA domain of p73 (lentimCherry-sgTAp73). We performed antibiotic selection and subcloned individual
A549 cells transduced with each of the lenti-mCherry-sgTAp73 viruses. To verify
accurate and efficient targeting of TAp73, we isolated genomic DNA from cells
expressing both GFP and mCherry and performed Sanger sequencing of the
genomic region flanking the targeted sequences of TAp73. Using this strategy, we
screened 16 clones and identified one clone (A549-sgTAp73) that exhibited a 34 bp
deletion of exon 2, which encompassed the corresponding targeting region for
sgTAp73 #2 (Figure 24A). Importantly, we found that this subclone showed
significantly reduced expressed of TAp73β compared to A549-Cas9 cells, as shown
by WB (Figure 24B).
To determine if the decreased T cell infiltration observed in the TK tumors
was due to dysregulated cytokine expression, we assayed the effect of TAp73depletion on cytokine secretion using a human cytokine antibody array. Stable A549Cas9 and A549-sgTAp73 cells were separately serum-starved and cultured in media
for 72 hours at which point conditioned media (CM) was collected and incubated
with the human cytokine antibody arrays prior to imaging (Figure 24C). From this
assay we identified a number of cytokines that were upregulated in the CM from
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A549-sgTAp73 cells, including IL-6, VEGF-A, and TGFβ3 (Figure 24CD).
Conversely, we identified a number of cytokines that are reduced in the TAp73deleted cells, including TNFβ, IGFBP-2, EGF, and angiogenin (Figure 24E). We
validated the increased amount of IL-6 in the CM of A549-sgTAp73 (Figure 24F),
and we are currently in the process of validating the other cytokines using ELISAbased assays. Taken together, these observations suggest that TAp73 may regulate
cytokine secretion of LUAC cells.
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Figure 24: Deletion of TAp73 using CRISPRi leads to deregulated cytokine
secretion. (A) Sequence of human TAp73 and the resulting deletion observed in
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cells following transduction with lentivirus expressing Cas9 and a TAp73-specific
guide RNA (sgTAp73), followed by antiobiotic selection and subcloning. (B) Western
blot analysis of TAp73 inA549 cells transduced with Cas9 or Cas9 plus sgTAp73 as
described in (A). (C-E) Cytokine array of A549-Cas9 vs. A549-sgTAp73 cells. List of
cytokines that are increased (D) and decreased (E) in A549-sgTAp73 cells (|Fc| >
1.5). Increased secretion of IL-6 is the most dramatic change in the A549-sgTAp73
cells (highlighted in red). (F) Increased secretion of IL-6 in A549-sgTAp73 cells was
validated by ELISA. Data shown is from a representative experiment (n=3).
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4.2.5. Depletion of TAp73 in human LUSC cell lines enhances tumor cell
migration and invasion.
Given the increased proportion of higher-grade lung tumors (e.g. Grade 2 and 3) in
TK mice, we examined whether siRNA-mediated knockdown of TAp73 in human
LUAC cell lines would enhance the migratory and invasive capacity of A549 cells
(Figure 25A). Notably, knockdown of TAp73 resulted in morphological changes that
resembled

an

epithelial-to-mesenchymal

transition.

(Figure

25B).

While

untransfected and siControl-transfected A549 cells exhibited an epithelial-like
morphology, characterized by colony forming cells with tight cell-cell contacts.
TAp73 knockdown cells showed a more mesenchymal phenotype characterized by
elongated spindle-like cells, and exhibiting fewer cell-cell contacts. These
observations were accompanied by significant increases in the migratory (Figure
25C) and invasive (Figure 25D) abilities of A549 cells following knockdown of
TAp73.
Similar to TAp73-knockdown cells, we found that A549-sgTAp73 cells
showed enhanced migratory capacity (Figure 25E). However, these cells did not
show enhanced invasion, nor did they exhibit the same dramatic EMT-like
phenotype of TAp73-knockdown cells (data not shown). In addition, we found that
these cells exhibited increased cell growth and proliferation (Figure 25saF). Taken
together, these results indicate that the depletion of TAp73 isoforms may enhance
the migratory capacity of human LUAC cells.
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Figure 25: Depletion of TAp73 in human LUSC cell lines enhances tumor cell
migration and invasion. (A) Western blot analysis showing successful siRNAmediated knockdown of TAp73 in the A549 human lung adenocarcinoma (LUAC)
cell line. (B) Phase contrast imagesof A549 cells transfected with the indicated
siRNAs. (C and D) Migration (C) and invasion (D) assays of A549 cells transfected
with the indicated siRNAs (n=2). (E and F) Migration (E) and cell growth curve (F) of
A549-Cas9 and A549-sgTAp73 cells.
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4.2.6. DISCUSSION
In this study, I have utilized an in vivo lung tumorigenesis model to test the effect of
TAp73 deletion on lung tumor formation. This system leverages a conditional
oncogenic Kras mutant mouse (KrasLSLG12D/+) (214) that, upon intratracheal
adenoviral Cre infection, develops lung adenocarcinomas with high frequency as
early as 16 weeks post infection (208). Supporting the notion that TAp73 functions
as a tumor suppressor, we found that the deletion of TAp73 in the context of
oncogenic Kras results in a significant increase in tumor development and
progression compared to oncogenic Kras activation alone. These results indicate
that TAp73 may inhibit both tumor initiation and progression in this context.
Interestingly, we found that the loss of TAp73 promotes tumor angiogenesis,
and a pro-tumorigenic immune environment. Immunohistochemical profiling showed
that

TAp73-deficient

tumors

exhibit

increased

tumor

vascularization,

as

demonstrated by increased CD31 staining. These observations support previous
studies that suggest that TAp73 is a suppressor of tumor angiogenesis (253, 254). In
addition, we found that the deletion of TAp73 in tumors resulted in reduced T cell
infiltration, as demonstrated by significant reductions in intratumoral CD3+, CD4+ and
CD8+ T cells. Taken together, these results suggest that TAp73-deficient tumors are
able to evade adaptive anti-tumor immune responses, through an as of yet
unidentified mechanism.
To identify the mechanism through which TAp73-deficient tumor cells evade
anti-tumor immunity, we employed a lentiviral based Crispr/Cas9 strategy to delete
TAp73 in the A549 human LUAC cell line. We then profiled the secretion of
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chemokines and cytokines from these cells and compared them to TAp73expressing A549 cells. The most significant changes include increased secretion of
IL-6 and TGFβ3 by TAp73-deleted A549 cells.
In addition, the depletion of TAp73 in human LUAC cell lines enhances tumor
cell proliferation. Inhibition of TAp73 also led to increases in cell migration and
invasion. Together, these observations suggest that TAp73 may mediate tumor
suppression through both cell- and non-cell-autonomous mechanisms.
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Chapter 5: DISCUSSION AND FUTURE DIRECTIONS
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Chapter 5: Discussion and Future Directions
5.1. Summary
TP63 and TP73 (which encode p63 and p73, respectively) are highly conserved
transcription factors with important roles in epidermal development, stratification,
and tissue homeostasis (23, 55, 183, 255). Similar to their homolog, p53, both p63
and p73 have been shown to mediate tumor suppression in multiple tissue types (3,
147, 185, 256). Interestingly, however, both genes are expressed as multiple
isoforms, which appear to have different, and, in many cases, antagonistic functions.
Through the use of isoform-specific null alleles of p63 and p73, our lab and others
have shown that the full-length N-terminal isoforms of p63 and p73 (referred to as
TAp63 and TAp73, respectively) exhibit distinct functions in development,
metabolism and tumor suppression (5-7, 14, 147). The goal of my thesis research
has been focused on understanding the specific functions of TAp63 and TAp73
isoforms in tumorigenesis. To do so, I have developed and employed novel
conditional knockout mouse models to investigate the tumor suppresive functions of
TAp63 and TAp73 in cutaneous squamous cell carcinoma (cuSCC) and lung
adenocarcinoma (LUAC), respectively.
First my research revealed important tumor suppressive functions of TAp63 in
cuSCC. Using a UVR-induced model of cuSCC, I found that TAp63-null (TAp63-/-)
mice exhibit increased susceptibility to cuSCC. Previously, our lab has previously
shown that TAp63 positively regulates miRNA processing, through direct
transcriptional activation of Dicer, as well as through the transcriptional activation of
individual pre-miRNA transcripts. In an effort to identify miRNAs regulated by TAp63

140

that predict cuSCC susceptibility, we performed RNA-seq from wild type and TAp63/-

skin and cuSCC lesions. Our data revealed significant perturbations in global

miRNA and mRNA expression in TAp63-deficient tumors. A human to mouse crossspecies analysis of the TAp63-/- cuSCC signature with similarly sequenced human
cuSCC lesions identified miR-30c-2* and miR-497 as significantly underexpressed in
both human and mouse tumors. Transfection of cuSCC cell lines with miR-497
mimics caused a dramatic decrease in proliferation.

Conversely, introduction of

miR-30c-2* mimics in cuSCC cell lines induced significant apoptosis. We
hypothesize that TAp63 mediates tumor suppression in the skin, in part, through the
anti-proliferative

and

pro-apoptotic

functions

of

miR-497

and

miR-30c-2*,

respectively. Through the use of quantitative proteomics, we have identified and
validated 7 direct targets of either miRNA, 2 of which are targeted by both miRs.
Ongoing experiments are aimed at identifying the therapeutic potential of inhibiting
the downstream targets of both miRNAs.
In addition to regulating miRNA expression, our lab and others have
discovered essential roles for p63 isoforms in the regulation of multiple stem cell
types in the skin and other tissues. While ΔNp63 isoforms appear to be critical for
maintaining basal keratinocytes (173, 257), our lab has also found that TAp63
isoforms are necessary for maintaining the replicative potential of skin-derived
precursors (SKPs), which are a type of stem cell present in the hair follicles of mice
and humans (14). SOX2, a transcription factor with established roles in stem cells
including SKPs (14, 258), is frequently overexpressed in human SCCs of the skin,
lung, head and neck, and others (73, 259). Interestingly, recent studies have found
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that SOX2 functions as regulator of cancer initiation and stemness in cutaneous
SCC (232, 233). Given their regulation by TAp63 and SOX2, I hypothesize that SKP
cells may serve as a potential cell of origin in cutaneous SCC. To test this
hypothesis, I have developed a novel lineage-tracing model to evaluate the tumor
initiating abilities of SOX2+ SKP cells in vivo. This system allows us to fluorescently
label SKP cells, as well as their descendants in vivo, thus allowing us to determine if
they can serve as a potential cell of origin. We are currently in the process of
finishing this experiment and are actively analyzing the data.
Along with TAp63-mediated tumor suppression in the skin, I have also found
that TAp73 functions as a tumor suppressor in the lung epithelium. To do so, I have
developed a novel TAp73 conditional knockout reporter mouse (TAp73fltd), which
effectively allows one to identify TAp73-deleted cells in situ. To investigate the role
of TAp73 in lung cancer, I crossed the TAp73fltd mice to a well-characterized mouse
model of Kras-driven LUAC. Using this model, I have found that the loss of TAp73
accelerates the initiation and progression of oncogenic Kras-driven LUAC. In line
with previous observations, TAp73 loss promotes tumor angiogenesis. Our data also
suggest that TAp73 may be necessary for tumor immune responses, as TAp73deficient lesions exhibit reduced T-cell infiltration. In addition, Crispr/Cas9 targeted
deletion of TAp73 in human lung adenocarcinoma cell lines resulted in aberrant
cytokine secretion, which may be the causative mechanism that drives the
decreased immune infiltration of TK tumors. Moreover, TAp73-deficient tumor cells
showed increased invasion and migration, indicative of an epithelial-to-mesenchymal
transition. Taken together these results suggest that TAp73 functions as a tumor
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suppressor in the lung, through both cell-autonomous, as well as non-cellautonomous mechanisms.

5.2. TAp63-regulated miRNA expression mediates tumor suppression in
cuSCC
Mechanistic studies have shown that TAp63 exhibits tumor suppressive functions
through transcriptional activation of genes involved in nucleotide excision repair (5),
cell death (260, 261), and metabolism (7). Recent studies have also implicated
TAp63 in the inhibition of metastasis through the activation of miRNA expression
and biogenesis (147, 262). In line with previous observations, this study
demonstrates that TAp63 may be a critical tumor suppressor of UVR-induced
cuSCC. Specifically, we see that mice lacking TAp63 are more susceptible to UVRinduced SCC, and that these mice have significantly altered miRNA and mRNA
expression profiles compared to strain-matched WT mice. Interestingly, we found
that many of the differentially expressed miRNAs and mRNAs in TAp63-/- cuSCC
were similarly deregulated in a previously published human cuSCC RNA-seq
dataset (72). Through the use of miRNA-mRNA functional pair analysis, we
identified a complex network miRNAs and mRNAs that are differentially expressed
and exhibit negative correlations in their expression, in both mouse and human
cuSCC. Subsequent validation showed the downregulation of miR-30c-2* and miR497 in both mouse TAp63-/- cuSCC and human cuSCC. Moreover, we found that
both miR-30c-2* and miR-497 expression is directly regulated by TAp63, and that
this regulation is Dicer-dependent (147).
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Through the use of miRNA mimics we were able to establish tumor
suppressive functions of miR-30c-2* and miR-497 in human cuSCC. Notably, miR30c-2* reduced cell proliferation and induced significant apoptosis in multiple cell
lines. Alternatively, we found that miR-497 overexpression did not induce cell death
but rather appeared to induce a striking G1/S cell cycle arrest and significantly
reduced cell proliferation. We further showed that re-introduction of miR-30c-2* and
miR-497 into tumor xenografts resulted in significantly reduced tumor growth, further
demonstrating the therapeutic potential of reintroducing these miRNAs and inhibiting
their targets.
miR-30c-2* is the passenger (miR*) strand of pri-miR-30c-2. Despite being
considered a passenger strand, the seed sequence of miR-30c-2* UGGGAGA is
highly conserved across mammals and reptiles, indicating the likelihood that it is a
functional miRNA. Both correlation and functional studies support the notion that
miR-30c-2* functions as a tumor suppressor in human cancers. For example, miR30c-2* has been shown to inhibit cell proliferation and angiogenesis through the
direct inhibition of HIF2α (263). miR-30c-2* was also found to inhibit NF-κB and cell
cycle progression in breast cancer cells via direct inhibition of TRADD and CCNE1
expression, respectively (264). Here, we show that miR-30c-2* overexpression
causes reduced cell proliferation, similar to previous observations. In addition, we
found that miR-30c-2* expression led to a highly significant induction of cell death,
which is a previously unobserved phenotype of miR-30c-2*. These results indicate
that miR-30c-2* is a tumor suppressive miRNA.
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miR-497 is the guide strand of pri-miR-497, which is encoded by the first
intron of the MIR497HG gene. It belongs to a larger family of miRNAs, referred to as
the miR-15/107 family, including miRs-15, 16, 103, 107, 195, 424 and 497, each of
which harbor the same seed sequence AGCAGC. Several of the miRNAs in this
family, including miR-497, are frequently underexpressed in human cancers (150,
265-267). Recent transcriptional profiling of human cuSCC tumors found that miR497 is consistently underexpressed in cuSCC and normal skin (72, 150).
Interestingly, both of these studies found that miR-497 expression is also
significantly reduced in actinic keratosis, which is a common pre-malignant lesion
that frequently progresses into fully malignant cuSCC. These results suggest that
loss of miR-497 expression may be an important event in the early stages of cuSCC
development. Functional studies support the notion that miR-497 functions as a
tumor suppressor, through its ability to regulate cell proliferation (242, 268-272),
apoptosis (273, 274), migration and invasion (275), and angiogenesis (276). In line
with previous studies, we found that miR-497 significantly suppresses cuSCC cell
growth, but it does not however induce apoptosis. This may be due to the
differences in the specific pathways that are regulated by miR-497 in cuSCC
compared to other tumor types. It may also be due to the differences in the level of
miR-497 overexpression that was achieved in the various studies. Regardless, our
data supports the general hypothesis that miR-497 is a tumor suppressive miRNA.
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5.3 Targets of miR-30c-2* and miR-497 as therapeutic targets
Multiple research groups have successfully delivered miRNA mimics in vivo to treat
preclinical models of human cancer (277). In fact, there are multiple companies with
patented technologies for delivering miRNA mimics that are currently in clinical trials.
Perhaps the most advanced compound is mRX34, a miR-34 mimic encapsulated in
a lipid carrier, which is currently being marketed by Mirna Therapeutics (278, 279).
In this study, we were unable to effectively treat xenograft lesions using synthetic
delivery of miR-30c-2* nor miR-497. In previous studies in vivo JETPEI had been
successfully used to deliver oligos, including miRNA mimics, to xenograft tumors.
The effectiveness of this treatment appears to be limited due to the limited delivery
of the mimics to the tumor tissues, and significant accumulation in the liver. We
therefore focused our attention on identifying downstream targets of miR-30c-2* and
mR-497 as an alternative means for identifying potential therapeutic interventions.
We utilized an unbiased proteomics approach to identify pathways that are
targeted by miR-30c-2* and miR-497 in cuSCC cells, which may mediate the
observed biological effects. In addition, global proteomic profiling is a more direct
high throughput method for identifying bona fide miRNA targets (280). Through
these experiments we found that miR-30c-2* inhibited the activity of multiple
pathways, including pathways related to ErbB signaling. The ErbB family of receptor
tyrosine receptors has been implicated in the pathogenesis of SCC, most notably
EGFR (68), which is mutated or amplified in a large percentage of different SCC
subtypes, including cuSCC (281).

Following miR-497 overexpression, we found

significant enrichment for pathways related to the regulation of mitotic progression,
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including Mitotic Roles of Polo-like kinase and Cell Cycle: G2/M DNA Damage
Checkpoint Regulation. These proteomic changes are in accordance with the
observed phenotypes of cells transfected with the corresponding miRNA mimic.
Interestingly, the only previously published targets of either miRNA that were
detected in these experiments included the miR-497 targets ANLN and CDK6 (243,
244). One potential mechanistic explanation for the dearth of previously published
targets of miR-30c-2* and miR-497 in the proteomics datasets may be differential 3’
UTR isoform usage (282). Additionally, the fraction of downregulated proteins in both
proteomics experiments were not enriched for MREs of miR-30c-2* or miR-497.
Remarkably, miRNA target prediction algorithms found that approximately equal
percentages of proteins in the underexpressed and overexpressed fractions of each
experimental condition were predicted to be targeted by the corresponding miRNA.
This may be due to the inaccurate nature of the prediction algorithms, which may be
explained by the fact that we, as a field, still have a limited understanding of the
mechanisms that fully govern miRNA-mediated repression (223). Our results prove
that prediction algorithms alone are insufficient for identifying bona fide miRNA
targets, and highlight the requirement for experimental validation.
Despite these limitations, the prediction software afforded an initial starting
point for target identification of either miRNA. We focused our search on relevant
targets of miR-30c-2* and miR-497 by comparing the list of underexpressed proteins
against the list of overexpressed mRNAs in the mouse TAp63-/- cuSCC and human
cuSCC RNAseq signatures. From this analysis, we identified five targets of miR-30c2* (FAT2, ITGA6, KIF18B, and PKMYT1) and four targets of miR-497 (AURKA,
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CDK6, PKMYT1, and KIF18B). We validated the direct targeting of 4/5 targets of
miR-30c-2* and all 4 targets of miR-497, through the use Western blotting and
miRNA pull-down assays. Interestingly, both miR-30c-2* and miR-497 are predicted
to target KIF18B, a kinesin that regulates microtubule dynamics at the plus end of
microtubules (283, 284), and PKMYT1 (aka Myt1), a protein kinase that inhibits
cyclin B-CDK1 activity via phosphorylation of CDK1 at T14 (285, 286).
Through the use of siRNA-mediated knockdown, we found that the inhibition
of the AURKA, KIF18B, PKMYT1, and ORC1 all resembled the phenotypes of the
overexpression of the corresponding miRNA. These results suggest that the
observed phenotypes of miR-30c-2* and miR-497 may be at least partially mediated
through the inhibition of these targets. CDK6, a serine/threonine kinase involved in
cell cycle progression had been previously shown to be a direct target of miR-497 in
hepatocellular carcinoma cells (241), indicating that this might be an important target
of miR-497 in different cancer types. Interestingly, inhibition of CDK6 had no effect
on cell growth or cell survival. This may be due to incomplete knockdown of CDK6,
or compensation from other CDKs, such as CDK2 and CDK4 (287, 288). Most
notably, we found that inhibition of AURKA using both siRNAs and alisertib, an FDAapproved AURKA-specific kinase inhibitor was most effective in suppressing tumor
cell proliferation and inducing apoptosis in both cell lines tested.
AURKA is a member of the Aurora family of serine/threonine kinases, which
play important functions in cell cycle regulation and mitotic progression. AURKA
phosphorylates a number of targets, and is required for recruiting CDK1-cyclin B1 to
the centrosome, where it phosphorylates CDC25B and contributes to the G2/M
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transition (289). AURKA is required for proper centrosome maturation and
duplication and bipolar spindle assembly (290). AURKA can also phosphorylate p53,
thereby inhibiting its transcriptional activity and reducing its protein stability (291,
292). Interestingly, AURKA overexpression has also been shown to inhibit the
transcriptional activity of TAp73 and p53, thereby suppressing their capacity to
induce apoptosis in response to DNA damage (293). Conversely, inhibition of
AURKA in cancer cell lines leads to the re-activation of TAp73 and p53-dependent
apoptosis. More recent mechanistic studies have revealed that AURKA directly
interacts with and phosphorylates p73 at serine 235, which inhibits the DNA-binding
and transcriptional activity of p73 (294). In turn, AURKA-dependent phosphorylation
of p73-S235 mediates resistance to DNA damage-induced cell death.
In this study, we found that that inhibition of AURKA resulted in a phenotype
that was reminiscent of mitotic catastrophe, similar to previously reported
phenotypes observed in other cancer cell types (295). These include reduced
proliferation and defects in spindle pole assembly and chromosome condensation
(296). This in turn results in defective chromosome segregation, ultimately causing
mitotic cell death (297, 298).
We also found that AURKA is frequently overexpressed in cuSCC, and that
its expression shows a significant negative correlation with miR-497. Previous
studies have shown that AURKA is frequently amplified and/or overexpressed in
multiple human tumor types (299, 300), and that high expression levels of AURKA
correlate with late clinical stage and metastasis in HNSCC (301). Likewise, we found
that high AURKA expression or decreased miR-497 expression correlates with poor
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survival. Given its oncogenic role, multiple AURKA inhibitors have been entered into
clinical trials (302). Perhaps the most efficacious of these inhibitors is alisertib, which
is an AURKA-specific inhibitor. Likewise, we found that inhibiting AURKA with
alisertib was highly effective in suppressing cuSCC cell growth and inducing cell
death. These results are notable, as targeting AURKA using alisertib, or any other
small molecule, has yet to have been pursued as a possible treatment option for
human cuSCC. Given the lack of FDA approved targeted therapies for advanced
cuSCC, this study may command further preclinical testing of AURKA inhibition in
the treatment of human cuSCC.
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Figure 26: Final Model. In normal cells, TAp63 promotes Dicer expression via
direct transactivation. Dicer, in turn, facilitates the maturation of miRNAs, including
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miR-497. These miRNAs can then inhibit the translation of select mRNAs, many of
which exhibit oncogenic functions. In this study, I found that miR-497 maintains
proper AURKA expression levels, which is necessary for proper centrosome
maturation, spindle alignment, and chromosome segregation during mitosis. In
cuSCC, however, TAp63 and Dicer expression is significantly reduced. As a result,
the maturation of tumor suppressive miRNAs, including miR-497 is compromised.
This leads to the de-repression of mRNAs, such as AURKA. Overexpression of
these targets may promote pro-oncogenic processes, such as inappropriate
proliferation and aneuploidy. Through this study, I have shown that the reintroduction of miR-30c-2* or miR-497 can suppress cuSCC survival and
proliferation. Additionally, inhibition of the miR-497 target AURKA was found to
suppress cuSCC growth and induce mitotic cell death. Together, the results of this
study suggest that this regulatory axis may present a novel avenue for therapeutic
intervention for the treatment of SCC.
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5.4. Investigating the putative cell of origin for cuSCC
In addition to regulating miRNA expression, our lab and others have discovered
essential roles for p63 isoforms in the regulation of multiple stem cell types in the
skin and other tissues. While ΔNp63 isoforms appear to be critical for maintaining
basal keratinocytes (173, 257), our laboratory has previously shown that TAp63 is
critical for maintaining the replicative potential of hair follicle stem cells within the
skin (14). These observations are of particular interest, given that multiple studies
suggest that hair follicle stem cells could serve as the cancer cell of origin for cuSCC
(234, 235, 303, 304). SOX2, a transcription factor with established roles in stem cells
including SKPs (14, 258), is frequently overexpressed in human SCCs of the skin,
lung, head and neck, and others (73, 259). Recent studies have also shown that
SOX2 functions as regulator of cancer initiation and stemness in cuSCC (232, 233).
Given their regulation by TAp63 and SOX2, I hypothesized that SKP cells may serve
be a potential cell of origin in cutaneous SCC. In addition, I hypothesized that TAp63
may prevent the transformation of SKP cells, and thereby prevent cuSCC initiation.
To test these hypotheses, I developed a novel lineage-tracing model to evaluate the
tumor initiating abilities of SOX2+ SKP cells in vivo. As of the date of this publication,
we have only analyzed tumor development in a subset of our cohort, which
developed a small number of papillomas and cuSCC. In vivo imaging and
immunohistochemical staining demonstrated however, that the majority of developed
tumors were GFP-negative. These results suggest that the tumors generated in this
study originated in a SOX2-negative precursor, suggesting that SOX2-positive SKP
cells may not be cell of origin for cuSCC. The technical limitations of these studies
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however preclude one from drawing a definitive conclusion about the tumor initiating
potential of this stem cell compartment. Moreover, it is difficult to know precisely how
efficiently the endogenous SKP cells underwent Cre-mediated recombination. It is
also unclear if the SKP cells that successfully undergo recombination are preserved
long enough to experience sufficient oncogenic changes (e.g. mutations), as a result
of UVR-treatment. While we did detect GFP positive hair follicles in mice after as
much as 44 weeks 4OHT treatment, it is uncertain if these cells are exposed to
sufficiently mutagenic UVR. Moreover, we have only analyzed a small proportion of
the UVR-treated cohort. We are currently irradiating more mice and are in the
process of fully characterizing the histopathological characteristics of the resulting
tumors that arise.

5.5. TAp73 suppresses lung adenocarcinoma development and progression
Similar to TAp63, TAp73 has been show to play a very important role in tumor
suppression. Previous studies found that germline deletion of TAp73 in mice leads to
the development of lung adenocarcinomas and lymphoma (185). Given these
observations, I have utilized an in vivo lung tumorigenesis model to test the effect of
TAp73 deletion on lung tumor formation. To do so, I generated cohorts of mice
bearing the following genotypes: 1) TAp73fltd/fltd 2) KrasLSLG12D/+ and 3) TAp73fltd/fltd;
KrasLSLG12D/+. These mice were treated with intratracheal delivery of adenovirus
expressing Cre (Ad-Cre) or empty vector (Ad-Empty). Thirty weeks after
intratracheal delivery of adenovirus, the mice were euthanized, necropsied, and
analyzed for the presence of lung tumors. Supporting the notion that TAp73
functions as a tumor suppressor, we found that the Ad-Cre infected TAp73fltd/fltd;
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KrasLSLG12D/+ mice showed a significant increase in tumor burden compared to the
KrasLSLG12D/+ mice. Upon closer histopathological examination, I found that there was
a significant increase in the proportion of high grade tumors (e.g. grade 3 and 4) in
TAp73fltd/fltd; KrasLSLG12D/+ mice compared to KrasLSLG12D/+ mice (208). These results
indicate that TAp73 may prevent the initiation and progression of Kras-driven LUAC.

5.6. Digital pathology and deep learning in preclinical models of LUAC
Manual grading of murine lung tumors and subsequent quantification showed that
there was a significant increase in the proportion of high-grade tumors (e.g. Grade 3
and Grade 4) (208) in tumors that developed in TAp73fltd/fltd; KrasLSLG12D/+ mice
compared to KrasLSLG12D/+. This quantification step, however, is laborious, and prone
to inaccuracies and possibly low reproducibility. Attempts to automate the grading of
these tumors using commercial software however were unsuccessful. Therefore, in
collaboration with the Analytical Microscopy and IRAT cores at Moffitt Cancer
Center, we aim to develop a Deep learning algorithm for digital pathology image
analysis of mouse lung tumor images. Such a system would allow us to automate
tissue and tumor segmentation.
An initial cohort of mice will be utilized as a training set for the development of
the tumor segmentation and grading algorithms. We have infected a larger validation
cohort of mice (each genotype consisting of more than 10 mice). These mice will be
euthanized at the 30-week post-infection time point and processed as described
above. Tumor sections will be stained using H&E and various immunohistochemical
stainings. Slides will be imaged in collaboration with the Analytical Microscopy core,
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and subsequently quantified using the newly developed algorithms. Parameters that
we are interested in quantifying include the number of tumors per tissue area,
percentage of tumor area, distribution of tumor grades, percentage stained cells,
staining intensity, etc. By utilizing serial sections of FFPE tissues, we aim to quantify
multiple parameters for individual tumors. This would allow for the correlation of
histopathological, molecular, and immunological characteristics of hundreds of
individual tumors, and provide massive amounts of statistical power to preclinical
studies.
This would improve the accuracy of image analysis, reduce observer bias,
and save researcher time. The conditional lung tumor model employed in this project
is widely used in preclinical studies of NSCLC (206, 208, 209, 211, 214, 231, 252,
305). Identification of lung micrometastases is also frequently scored in other studies
examining the underlying biology of tumor metastasis. Therefore, other research
labs would stand to benefit from automated digital pathology that is tailored to
mouse lung tissue segmentation.

5.7. TAp73 as a putative regulator of adaptive anti-tumor immune responses
Early studies in mice suggested that p73 may play a role in normal immune cell
functions. These observations were most clearly demonstrated in Trp73-/- mice,
which frequently die from infections just a few weeks after birth (183). Subsequent
studies demonstrated these functions may be isoform-specific. For example, TAp73/-

mice are significantly more sensitive to lipopolysaccharide challenge, showing

higher levels of proinflammatory cytokines in the blood and greater mortality
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compared to wild-type mice (10). In addition, TAp73-/- macrophages were found to
secrete higher levels of TNFα, IL-6, and macrophage inflammatory protein-2. These
observations suggest that the loss of TAp73 favors the M1 effector phenotype, as
opposed to the M2 phenotype. In turn, the normal progression of the inflammatory
response is dysregulated.
To determine if the loss of TAp73 facilitates a pro-tumorigenic immune
environment, we utilized immunohistochemical (IHC) stainings to profile various
immune markers in the lungs of Ad-Cre infected mice. Through these studies we
found that TAp73-deficient lesions exhibited significant increases in CD31 staining,
indicating increased angiogenesis in these tumors. Interestingly, there are conflicting
studies relating to the function of TAp73 in the regulation of cellular responses to
hypoxia, including angiogenesis (253, 254, 306). Our results are in accordance with
previous studies, which have shown that TAp73 inhibits angiogenesis in tumors
(253, 254). Specifically, Amelio et al. suggest that TAp73 inhibits tumor
angiogenesis through the degradation of HIF1α, which is in line with our data.
Liekwise, Stantic et al found that the loss of TAp73 leads to highly vascularized
tumors, and that the inhibition of TAp73 leads to increased HIF1α and HIF1α target
genes. Loss of ΔNp73, on the other hand caused a reduction in tumor
vascularization. Conversely, Dulloo et al. suggests that TAp73 is induced by hypoxia
and, in turn, regulates the transcription of pro-angiogenic genes, including vegf-A
(306). Nevertheless, our data highlights the anti-angiogenic functions of TAp73,
particularly in the context of autochthonous lung tumors.
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In addition to increased tumor angiogenesis, we also found that TAp73deficient tumors exhibit reduced T cell infiltration, as demonstrated by significant
reductions in intratumoral CD3+, CD4+ and CD8+ cells. The expression of
intratumoral PD-L1 and FOXP3, however, showed no significant changes between
either genotype. These observations suggest that the observed decrease in the
infiltration of T cells was not due to the dysregulation of these immune checkpoint
signals. Taken together, these results suggest that TAp73-deficient tumors are able
to evade adaptive anti-tumor immune responses, through an as of yet unidentified
mechanism.
To ascertain the mechanism through which TAp73-deficient tumor cells evade
anti-tumor immunity, we employed a lentiviral based Crispr/Cas9 strategy to delete
TAp73 in the A549 human LUAC cell line. Using this strategy, we were able to
generate a single A549 cell line that exhibited a deletion in exon 2 of TAp73 (A549sgTAp73), resulting in a frameshift mutation and a near total loss of TAp73
expression. We then profiled conditioned media from A549-sgTAp73 and A549Cas9 for the secretion of a large proportion of the known human cytokines. Using
this strategy, we found that the secretion of a subset of cytokines is significantly
affected in the A549-sgTAp73 cells. The most significantly affected change we found
was increased IL-6 secretion in TAp73-deficient cells. We are currently collaborating
with an immunologist to better characterize the putative mechanisms through which
these deregulated cytokines may impact T cell infiltration and anti-tumor responses.
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5.8. Conclusions and future directions
The p53 family of transcription factors regulates a vast transcriptional network, which
is important for normal development and tumor suppression. These processes
include, but are not limited to, cell cycle arrest, senescence, apoptosis, and
metabolic regulation. The presence of multiple, complex isoforms of p53, p63 and
p73, however, have made it difficult to understand the specific functions of these
genes in various contexts. While p53, TAp63, and TAp73 can transactivate the
expression of genes involved in tumor suppressive pathways, the N-terminally
truncated isoforms, ΔNp63 and ΔNp73, can suppress this transcriptional activation.
In line with these observations, I have been able to demonstrate that the full-length
TAp63 and TAp73 isoforms function as tumor suppressors in cuSCC and LUAC.
First, I have found that TAp63 functions as a tumor suppressor in cuSCC
through the regulation of miRNAs. Identified miR-30c-2* and miR-497 as being
positively regulated by TAp63 through Dicer-dependent processing. These two
miRNAs may present novel therapeutic targets in human cuSCC. Moreover, through
the integration of next generation RNA sequencing and quantitative proteomics, I
have identified multiple, novel direct targets of these miRNAs. In turn, I have found
that these targets may be functionally relevant to the initiation and progression of
cuSCC. Among these targets are several kinases, for which there are FDA-approved
small molecule inhibitors. My results suggest that among these targets, the
serine/threonine kinase AURKA may be the most promising target for therapeutic
intervention. Alisertib, which is an FDA-approved AURKA inhibitor, is currently being
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investigated as a targeted therapy in multiple solid tumor types, however it has not
been tested in human cuSCC.
Likewise, I have shown that TAp73 functions as a tumor suppressor in the
lung epithelium. Through the use of a well-characterized mouse model of LUAC, I
have found that the loss of TAp73 accelerates the initiation and progression of
oncogenic Kras-driven LUAC. Further characterization of the resulting tumors
suggests TAp73 may mediate tumor suppression through cell- and non-cellautonomous mechanisms. Interestingly, the loss of TAp73 in oncogenic Kras-driven
LUAC appears to inactivate anti-tumor adaptive immune responses, which may
account for the increased tumor burden in these mice. In addition, inhibition of
TAp73 expression in human LUAC cell lines resulted in increased invasion and
migration. Together, these observations suggest that TAp73 may regulate multiple
pathways that prevent the initiation and progression of LUAC.
Altogether, my thesis research has uncovered novel functions of TAp63 and
TAp73, highlighting the important roles these genes play in tumor suppression.
Future research should focus on understanding the molecular mechanisms that
regulate the isoform-specific functions of p63 and p73 in different cellular contexts
and disease states. Current work in our laboratory aims to uncover the molecular
biology that regulates the functions of the p53 family in human cancer. These
studies, in addition my thesis research, reveal new avenues for investigating novel
targeted therapies and diagnostic biomarkers.
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Appendix 1: Genetically engineered mouse models harboring mutations in the
p53 family members.

Phenotypes:
Genotype*:

Development:

Tumorigenesis:

References:

-/-

Perinatal lethality

Lymphoma, testicular teratoma, sarcomas

(307)

+/-

Intestinal polyps

Lymphoma, carcinomas, sarcomas

(307)

Incomplete limb development,
craniofacial malformations, near
complete lack of epidermis*

unknown

(55)

Incomplete limb development,
craniofacial malformations, complete
lack of epidermis*

unknown

(23)

+/-

Premature aging

Lung adenoma, squamous cell carcinoma,
hystiocytic sarcoma

(184)

+/-

Premature aging

Epithelial hyperplasia

(308)

+/-

Developmentally normal

Lymphoma, lung adenocarcinoma,
hemangiosarcoma

(184)

Postnatal lethality, decreased body
size, chronic inflammation, rhinitis,
intracranial hemorrhage,
hydrocephaly, hipoocampal
dysgenesis

Lung adenocarcinoma

(183)

Premature aging, partial paralysis

Metastatic sarcomas and carcinomas,
osteosarcoma, rhabdomyosarcoma,
hemangiosarcoma, mammary
adenocarcinoma, lung adenocarcinoma,
salivary adenoma, squamous cell carcinoma,
leukemia, lymphoma
(184)

Premature aging

Metastatic sarcomas and carcinomas,
osteosarcoma, rhabdomyosarcoma,
mammary adenocarcinoma, squamous cell
carcinoma, leukemia, transitional cell
carcinoma

Premature aging

Metastatic sarcomas and carcinomas,
osteosarcoma, hemangiosarcoma, lung
adenocarcinoma, pancreatic
adenocarcinoma, hepatocellular carcinoma,
lymphoma
(184)

Trp53 (tm1Tyj)

Trp53 (tm1Tyj)

-/-

Trp63 (tm1Fmc)

-/-

Trp63 (tm1Brd)

Trp63 (tm1Fmc)

Trp63 (tm1Brd)

Trp73 (tm1Fmc)

-/-

Trp73 (tm1Fmc)

+/-

Trp63 (tm1Fmc);
+/Trp73 (tm1Fmc)

+/-

Trp53 (tm1Tyj);
+/Trp63 (tm1Fmc)

+/-

Trp53 (tm1Tyj);
+/Trp73 (tm1Fmc)
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(184)

Appendix 2: Genetically engineered mouse models harboring isoform-specific
deletions of p63 and p73

Phenotypes:
Genotype*:

Development:

Tumorigenesis:

Fertility defects, skin blistering, woundhealing defects, decreased hair follicle
morphogenesis, premature aging,
diabetes and obesity

Metastatic sarcomas and carcinomas,
osteosarcoma, histocytic sarcoma,
rhabdomyosarcoma, angiosarcoma, lung
adenocarcinoma, hepatocellular carcinoma,
mammary adenocarcinoma, squamous cell
carcinoma, transitional cell carcinoma,
lymphoma
(7, 14, 147)

+/-

unknown

Metastatic sarcomas and carcinomas,
osteosarcoma, histocytic sarcoma,
rhabdomyosarcoma, angiosarcoma, lung
adenocarcinoma, mammary
adenocarcinoma, squamous cell carcinoma,
lymphoma
(147)

-/-

Oocytes are resistant to DNA damage

unknown

(309)

-/-

No overt phenotypes

unknown

(3)

unknown

Metastatic sarcomas and carcinomas,
osteosarcoma, rhabdomyosarcoma, lung
adenocarcinoma, mammary
adenocarcinoma, squamous cell carcinoma,
transitional cell carcinoma, thyroid
carcinoma, lymphoma
(147)

unknown

Metastatic sarcomas and carcinomas,
osteosarcoma, histocytic sarcoma,
rhabdomyosarcoma, angiosarcoma, lung
adenocarcinoma, mammary
adenocarcinoma, squamous cell carcinoma,
transitional cell carcinoma, lymphoma
(147)

unknown

Metastatic sarcomas and carcinomas,
osteosarcoma, histocytic sarcoma,
rhabdomyosarcoma, angiosarcoma,
mammary adenocarcinoma, squamous cell
carcinoma, lymphoma, CML

unknown

Metastatic sarcomas and carcinomas,
osteosarcoma, histocytic sarcoma,
rhabdomyosarcoma, angiosarcoma, lung
adenocarcinoma, mammary
adenocarcinoma, squamous cell carcinoma,
intestinal carcinoma, salivary carcinoma,
lymphoma
(147)

-/-

TAp63 (tm1.1Elrf)

TAp63 (tm1.1Elrf)
TAp63 (tm2Fmc)
TAp63 (tm2.1Aam)

-/-

TAp63 (tm1.1Elrf);
+/Trp53 (tm1Tyj)

+/-

TAp63 (tm1.1Elrf);
+/Trp53 (tm1Tyj)

+/-

TAp63 (tm1.1Elrf);
-/Trp53 (tm1Tyj)

-/-

TAp63 (tm1.1Elrf);
-/Trp53 (tm1Tyj)
-/-

TAp73 (tm1Mak)
+/-

TAp73 (tm1Mak)

Infertility; prenatal lethality, hippocampal Lung adenocarcinoma, lymphoma, colon
dysgenesis
carcinoma

unknown

Lung adenocarcinoma, thymic lymphoma,
colon carcinoma, hemangiosarcoma
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References:

(147)

(185)

(185)

Appendix 3: Differentially expressed miRNAs in both mouse TAp63-/- cuSCC
and human cuSCC.

Mouse miRNA:

Expression fold change:
-/TAp63 mouse SCC vs. skin

Human miRNA:

Fold change:
Human SCC vs. skin

1

mmu-mir-338-5p

0.167679401

hsa-mir-338-5p

0.432580953

2

mmu-mir-30c-2-3p

0.352337693

hsa-mir-30c-2-3p

0.52321724

3

mmu-mir-146b-5p

0.453765561

hsa-mir-146b-5p

0.564316928

4

mmu-mir-145a-5p

0.578539783

hsa-mir-145-5p

0.245186413

5

mmu-mir-497-5p

0.581987169

hsa-mir-497-5p

0.562252492

6

mmu-mir-27b-3p

1.593852492

hsa-mir-27b-3p

1.814517203

7

mmu-mir-151-3p

1.972782325

hsa-mir-151a-3p

2.076184467

8

mmu-mir-27b-5p

2.075598463

hsa-mir-27b-5p

1.814517203

9

mmu-mir-15b-3p

2.388412156

hsa-mir-15b-3p

2.253178485

10

mmu-mir-17-3p

2.815433075

hsa-mir-17-3p

1.996950466

11

mmu-mir-106b-5p

2.891542541

hsa-mir-106b-5p

1.97486852

12

mmu-mir-93-5p

3.06542905

hsa-mir-93-5p

1.575598665

13

mmu-mir-17-5p

3.473403521

hsa-mir-17-5p

1.996950466
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